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Abstract
Background:
Young adults with Type 1 Diabetes have low circulating concentrations of IGF-I with
consequent GH hypersecretion. This results in reduced insulin sensitivity and may be
implicated in the risk ofmicrovascular complications, particularly nephropathy.
Abrogation of these abnormalities may facilitate more normative metabolic and renal
physiology and lead to the development of adjunctive therapies for use in this vulnerable
population.
Aims:
1) To investigate the effects of specific GH blockade on insulin sensitivity and
carbohydrate and lipid metabolism in young adults with Type 1 Diabetes.
2) To investigate the effects of restoration of circulating IGF-I concentrations by
administration of rhIGF-I complexed with rhIGFBP-3 on GH secretion, overnight
insulin requirements, glomerular filtration rate, urinary albumin excretion rate and
proteolysis of IGFBP-3.
Methods:
1) In a crossover study, 2 doses (5 and lOmg) of a specific GH antagonist (B2036-PEG,
Somavert) were each administered for 3 weeks to 7 subjects, in random order with a 3
week washout period. Euglycaemic clamp techniques incorporating cold isotopes were
used to quantify carbohydrate and fat metabolism at baseline and following GH
blockade.
2) In a double blind placebo controlled crossover study, rhIGF-I/rhIGFBP-3 complex
(0.4mg/kg/day) was administered to 6 subjects for 7 days. Overnight GH secretion,
insulin requirements, glomerular filtration rate and urinary albumin excretion rate were
determined at the end of each treatment period. Proteolysis of IGFBP-3 was assessed
using western immunoblotting techniques of plasma and urine before and following
administration of rhIGF-I/rhIGFBP-3 complex.
Results:
1) Selective GH blockade using B2036-PEG led to reductions in IGF-I concentrations,
reductions in insulin requirement and suppression of lipolysis overnight. During a
hyperinsulinaemic euglycaemic clamp, there was no effect on glucose or glycerol
turnover.
2) Administration of rhIGF-I/rhIGFBP-3 complex led to increases in IGF-I
concentrations and suppression of endogenous GH secretion. Overnight insulin
requirements were reduced and there was no effect either on glomerular filtration rate or
urinary albumin excretion rate. Following rhIGF-I/rhIGFBP-3 complex administration
there appeared to be an induction of the proteolysis of IGFBP-3 within 7 hours, with
subsequent excretion of proteolysed fragments in the urine.
Conclusion:
Blockade of the action of excessive GH or suppression of endogenous secretion ofGH
using novel compounds in Type 1 Diabetes leads to reductions in overnight insulin
requirements. Failure to observe effects on other parameters may reflect opposing
actions of IGF-I and GH on insulin sensitivity and GFR or the limitations of
hyperinsulinaemic clamp methodology. Further evaluation of the clinical relevance of
such interventions in larger scale clinical trials would be of interest.
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Chapter 1: INTRODUCTION
1.1. Type One Diabetes Mellitus at Puberty
The management of diabetes during puberty and adolescence presents a number of
challenges. The ideal is to achieve optimal glycaemic control in order to minimise the
risk of long-term complications by using an insulin regimen that is acceptable to the
individual (DCCT, 1994). During adolescence, it is notoriously difficult to achieve
adequate glycaemic control and a rise in HbAlc is almost inevitable (Holl, Swift et al.
2003). Attempts to improve control by intensification of insulin therapy may result in
unacceptable side effects such as hypoglycaemia (particularly at night) and inappropriate
gains in fat mass (DCCT, 1994). Results from large international studies aiming to
intensify treatment in this vulnerable population in order to improve glycaemic control
and reduce the risk of complications are generally disappointing (Mortensen, Robertson
et al. 1998; Holl, Swift et al. 2003).
The management of diabetes during puberty and adolescence is a complex problem,
requiring the input of a cohesive multidisciplinary team incorporating a number of
essential professionals such as paediatric diabetes specialist nurses, dieticians and
psychologists in addition to a paediatrician, with all team members communicating
similar goals and expectations to the young person and their family in order to optimise
glycaemic control (Hoey, McGee et al. 2006). The adolescent with diabetes is a
vulnerable individual, at risk of the complications of diabetes as well as of psychological
disturbance. Worryingly, large numbers may become lost to follow up during their
transition from the paediatric to the adult clinic, meaning they have no regular input
from specialist diabetes teams, and, importantly, no regular screening for the more
common complications of diabetes such as retinopathy and microalbuminuria (Bryden,
Peveler et al. 2001).
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Whilst the effects ofpsychological factors such as rebellion and difficulties with
concordance cannot be ignored, there are very real physiological influences during
puberty, notably the actions of growth hormone and the sex steroids, which can
negatively impact on diabetes management during puberty and adolescence (Dunger
1992). Adolescents with Type 1 Diabetes have well described abnormalities of the
growth hormone - IGF-I axis, with low circulating concentrations of IGF-I and hyper
secretion of growth hormone which leads to insulin resistance, often manifesting as the
'dawn phenomenon' ofmorning hyperglycaemia (Edge, Dunger et al. 1990; Edge,
Matthews et al. 1990). This phenomenon may impede attainment of tight glycaemic
control, as increasing evening doses of intermediate or long acting insulin in order to
achieve fasting blood sugars within target, may result in inappropriate insulin
concentrations in the early hours of the morning with associated hypoglycaemia (Amin,
Ross et al. 2003).
Over recent years, the development of insulin analogues, with more attractive
pharmacokinetic profiles, has had encouraging effects on rates of overnight
hypoglycaemia, with some beneficial effects on glycaemic control in the paediatric
population (Mohn, Matyka et al. 1999; Murphy, Keane et al. 2003). However, the
pharmacokinetic profiles of the insulin analogues still remain far from ideal and the
fluctuation in basal insulin requirements over a 24 hour period can only really be
reproduced by continuous subcutaneous insulin infusion (CSII) via a pump (Tamborlane
and Press 1984). CSII is used extensively in the USA and Scandinavia and its use in
children is gradually becoming more commonplace in the United Kingdom. Introduction
of pump therapy leads to improvements in glycaemic control, with reductions in total
daily insulin dose and reduced rates of hypoglycaemia (Boland, Grey et al. 1999). They
are, however expensive and as their use becomes more widespread, robust confirmation
of efficacy within the paediatric population in terms ofHbAlc has yet to be achieved
(Nahata 2006), although most studies consistently report improvements in quality of life,
reductions in total daily insulin dose and reduced rates of hypoglycaemia (Juliusson,
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Graue et al. 2006). Within England and Wales, the use ofCSII in children is subject to
guidance by the National Institute of Health and Clinical Excellence (NICE) which
recommends them only in children if multiple daily injection therapy is deemed
unsuitable (children <1 lyr) or if adequate glycaemic control is unacceptable
(HbAlc>8.5%), or in the face of severe and disabling hypoglycaemia.
In the adolescent with diabetes, although insulin deficiency is clearly the primary
endocrinopathy, the influence of other hormonal perturbations, particularly those of the
growth hormone IGF-I axis are also important and the abnormalities of this axis will be
discussed in detail later in this chapter. Growth hormone hypersecretion leads to
increased insulin resistance and may independently contribute to the risk of development
ofmicrovascular complications, in particular, nephropathy. More detailed understanding
of the dysregulation of this axis and its physiological effects may permit the
development of alternative strategies for therapy, in an attempt to mimic more normative
physiology. Such strategies could be used in conjunction with optimal insulin
replacement therapy in the vulnerable adolescent population in order to reduce the risk
of complications by means independent of glycaemic control. In addition, manipulation
of this axis in the young person with Type 1 Diabetes gives a unique opportunity for
furthering our understanding of the physiological and metabolic effects of growth
hormone and its dependent peptides.
1.2. Growth Hormone
1.2.1 Regulation ofSecretion
Growth hormone is a non-glycosylated, single chain, 191 amino acid, 22 -kDa protein
which is synthesised and secreted mainly by somatotrophs located in the lateral
segments of the anterior pituitary gland (Kopchick, Parkinson et al. 2002). Growth
hormone is released in a pulsatile fashion due to the interaction of 2 hypothalamic
factors; Growth hormone releasing hormone (GHRH) and Somatostatin, which stimulate
and inhibit its release respectively (Figure 1) (Muller, Locatelli et al. 1999). GHRH and
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Somatostatin are themselves released in pulses and the integration of these, together with
the influence of numerous other growth hormone secretogogues, results in the classical
pulsatility of endogenous growth hormone release, reviewed comprehensively in
Physiological Reviews, 1999 (Muller, Locatelli et al. 1999). Patterns ofGHRH and
Somatostatin release are themselves determined by the complex interaction of
neurotransmitters, neuropeptides and opioids, and so the final secretory pattern of
growth hormone is the end result of an elegant and complex interaction between
numerous regulators (Muller, Locatelli et al. 1999).
At the cellular level, the mechanism of growth hormone release by somatotrophs is
dependent upon a cyclic AMP (cAMP) mediated rise in intracellular calcium
concentration with subsequent induction of the transcription of pituitary specific
transcription factors such as pit-1 (Giustina and Veldhuis 1998). GHRH leads to a rise,
and Somatostatin to a fall, in intracellular calcium concentration and thus they have
opposing effects on growth hormone secretion (Melmed and Kleinberg 2003).
Under normal circumstances, maximal growth hormone secretion occurs in the early
part of the night during slow wave sleep, but also forms part of the physiological
response to a variety of stresses such as prolonged fasting, exercise, trauma,
hypovolaemia and hypoglycaemia (Isidori, Fraiolo et al. 1976; Sutton and Lazarus
1976). The quantity of growth hormone secreted declines with age and is suppressed
during chronic illness, depression or psychosocial deprivation in children (Melmed and
Kleinberg 2003). In addition to regulation by the hypothalamic factors described above,
growth hormone secretion is also subject to classical negative feedback inhibition; with
growth hormone inhibiting the release ofGHRH by the hypothalamus and insulin like
growth factor I (IGF-I) inhibiting both GHRH release at the level of the hypothalamus
(long loop) and growth hormone release by the pituitary gland (short loop) (Figure 1).
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1.2.2 Receptor Binding andDownstream Signalling
Growth hormone exerts its effects at target tissues via its receptor (GHR), which consists
of an extracellular domain (for ligand binding) linked to a signalling region located on
the cytoplasmic side of the cell membrane by a single membrane spanning region
(Leung, Spencer et al. 1987). The GHR is ubiquitously expressed in all tissues in
humans, however the highest levels of expression occur in bone (at the growth plate),
liver, fat and muscle (Kopchick, Parkinson et al. 2002). Binding to the receptors in these
tissues effects the growth promoting and metabolic actions of growth hormone which
will be described in more detail later in this chapter.
Figure 1: Regulation ofGrowth Hormone Secretion
Schematic representation of the central mechanisms (both negative and positive) of the
control of endogenous growth hormone secretion. [GH: Growth Hormone, GHRH: GH
Releasing Hormone, SS: Somatostatin, IGF-I: Insulin-like growth factor-I],
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Each growth hormone molecule contains 2 receptor binding sites, which allow binding
to a GHR dimer, comprising 2 GHR molecules closely approximated on the cell
membrane (Gent, Van Den Eijnden et al. 2003). Binding of a single growth hormone
molecule to the receptor dimer, effects a conformational change in the intracellular
portion of the receptor (Figure 2), and results in activation of an intracellular kinase;
Janus Kinase 2 (JAK2) (Carter-Su, Schwartz et al. 1996). Subsequently, phosphorylation
leads to activation of intracellular transcription molecules, (specifically the 'signal-
transducing activators of transcription' proteins (STATs)), which are then translocated to
the nucleus where they bind to DNA and regulate transcription of growth hormone
specific genes (Xu, Wang et al. 1996). GHR molecules are subsequently internalised
within clathrin-coated vesicles and transported to the lysosomes where they are degraded
and recycled (Kopchick, Parkinson et al. 2002).
At the cellular level, the actions of growth hormone are terminated by the 'suppressor of
cytokine signalling', or SOCS proteins which inhibit the JAK2 facilitated translocation
of STAT proteins to the nucleus, this disrupting GH signalling (Starr and Hilton 1998).
h| A
Cell Membrane L-J
A: Human Growth Hormone Receptor in
unoccupied state
B: Bound to human growth hormone (hGH)
Conformational change leads to activation of
downstream signalling pathways
Figure 2: Human Growth Hormone Receptor Signalling
Schematic representation ofHuman Growth Hormone Receptor activation and signalling
A: Inactive Form B: Bound to human growth hormone.
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In addition to activation of its own signalling cascade, the binding of growth hormone to
its receptor also affects several other intracellular signalling pathways, notably that of
insulin; leading to phosphorylation of both insulin receptor subunits 1 and 2 (IRS-1 and
IRS-2) (Carter-Su, Schwartz et al. 1996). Such subtle and intricate interaction of the
intracellular signalling pathways of different molecules is an example of the exquisite
regulation ofmetabolism at a molecular level and is, as yet, far from fully understood
(Carter-Su, Schwartz et al. 1996; Dominici, Argentino et al. 2005).
1.3. The Metabolic Effects of Growth Hormone
In addition to regulating growth at the growth plate, both directly and also indirectly via
the generation of IGF-I, growth hormone has a number of effects on metabolism. It has
anabolic effects on muscle; enhancing protein synthesis, it stimulates lipolysis leading to
alterations in patterns of fat deposition and also affects glucose metabolism, leading to
reductions in insulin sensitivity (Melmed and Kleinberg 2003). The effects of growth
hormone on fat turnover and on insulin sensitivity will now be discussed in further
detail.
1.3.1 Fat Metabolism
Growth hormone has well described effects on lipid metabolism; its predominant effect
being the stimulation of lipolysis that leads to release of non-esterified free fatty acids
(NEFA) from adipocytes (Piatti, Monti et al. 1999). Moller and colleagues performed
detailed physiological studies in 6 healthy volunteers, each of whom was studied on 2
occasions, once following an infusion of growth hormone (20mU/kg/min for 4 hours)
and once following an infusion of 0.9% sodium chloride (Moller, Jorgensen et al. 1990).
After the infusion of growth hormone, there was evidence of a rapid induction of
lipolysis, in conjunction with a 40 to 50% reduction in glucose utilisation in the forearm.
There was a rapid rise in concentrations of free fatty acids and p-hydroxybutyrate which
peaked after 2 to 3 hours (Moller, Jorgensen et al. 1990). The same group carried out
detailed physiological studies of the effects of different doses (70, 140 and 350
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micrograms administered as an intravenous pulse) of growth hormone on parameters of
glucose and lipid metabolism, reporting dose-dependent effects on lipolysis, but not on
glucose metabolism (Moller, Schmitz et al. 1992).
Adults with growth hormone deficiency have marked aberrations of serum lipid
parameters; increased cholesterol, decreased HDL cholesterol, a decreased HDL: LDL
ratio and increased triglycerides, a cluster of parameters that confers an increased risk of
cardiovascular disease (de Boer, Blok et al. 1995). Growth hormone deficiency in adults
manifests as a recognisable syndrome that includes impaired quality of life, body
composition changes including increased fat mass with altered distribution and increased
risk of cardiovascular disease and stroke (Salomon, Cuneo et al. 1989). In contrast, in
the hypersomatotropic state of acromegaly there is insulin resistance as demonstrated by
increased fasting glucose, insulin and C-peptide concentrations combined with a 50%
greater rate of lipid oxidation than control subjects, differences which largely disappear
following pituitary surgery with subsequent appropriate replacement of anterior
pituitary hormones (Moller, Schmitz et al. 1992).
1.3.2 Insulin Sensitivity
The predominant insulin responsive tissues in man are liver, muscle and fat (Melmed
and Kleinberg 2003). In liver, insulin suppresses endogenous hepatic glucose production
from the breakdown of hepatic glycogen and stimulates glycogen synthesis. In muscle,
insulin stimulates the uptake of glucose for peripheral utilisation and the synthesis of
muscle glycogen and in fat; hormone sensitive lipase is exquisitely sensitive to insulin,
with relatively low concentrations of insulin leading to almost complete suppression of
lipolysis and induction of lipogenesis. Following a meal, insulin release into the portal
circulation in response to enteral feeding, signals the switch from the fasting to the fed
state.
The quantification and description of insulin sensitivity is complicated by the use of
many different methodologies, however the hyperinsulinaemic euglycaemic clamp
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technique incorporating the use of cold isotopes allows the estimation of contribution of
both hepatic and peripheral (predominantly muscle) insulin sensitivity and is considered
to be the gold standard methodology (DeFronzo, Tobin et al. 1979). Hepatic and
peripheral insulin sensitivity can be considered separately; hepatic insulin sensitivity
reflecting the amount of insulin required to suppress hepatic glucose production during a
fast (for example overnight) and peripheral insulin sensitivity reflecting the rate of
insulin stimulated glucose uptake by muscle (for example following a meal) (DeFronzo,
Tobin et al. 1979).
Growth hormone has been known to have effects on glucose homeostasis since the
1930s when Houssay described a reduction in the blood sugars of dogs with
experimental diabetes following hypophysectomy (Houssay and Biasotti 1930). Growth
hormone was subsequently isolated from pituitary extracts and confirmed as the
diabetogenic agent. Since then the details of the cellular and molecular mechanisms by
which growth hormone influences insulin action have been extensively (but by no means
exhaustively) characterised.
Growth hormone has effects both on hepatic and peripheral insulin sensitivity in
humans. In healthy volunteers, approximately 5 hours after administration of a Growth
hormone bolus, there is a right shift in the dose response curve of both hepatic glucose
production and peripheral glucose utilisation to insulin (Rizza, Mandarino et al. 1982),
implying that growth hormone has effects both on hepatic and peripheral insulin
sensitivity. The reduction in insulin sensitivity following growth hormone administration
may be mediated via effects on the insulin-signalling pathway. There are common
elements to the signalling mechanisms of both the insulin and growth hormone
receptors; notably the kinase, JAK 2 (Carter-Su, Schwartz et al. 1996). Interaction at the
intracellular level following activation of either or both receptors is likely to provide a
mechanism by which growth hormone and insulin can influence each other's actions,
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however, the exact nature of this subtle interaction remains to be determined (Carter-Su,
Schwartz et al. 1996).
Growth hormone may also influence insulin sensitivity indirectly, by its effects on
lipolysis. Growth hormone stimulates lipolysis, leading to elevations in circulating
concentrations of free fatty acids (FFA) (Piatti, Monti et al. 1999). FFAs have long been
known to correlate inversely with insulin sensitivity. In the 1960s, Sir Philip Randle
proposed the glucose fatty-acid cycle, whereby fatty acids induce insulin resistance in
muscle, by the inhibition of phosphofructokinase and subsequent inhibition of cellular
glucose uptake (Randle, Garland et al. 1963). More recently, the development of nuclear
magnetic resonance (NMR) spectroscopy has permitted quantification of intra- and
extra-myocellular triglycerides and confirmed that an increase in plasma fatty acid
concentration leads to reductions in glucose uptake by the myocyte (Shulman 2000).
This is likely to be secondary to an accumulation of intramyocellular fatty acyl coA in
conditions of elevated plasma fatty acids, with subsequent effects on downstream
signalling from the insulin receptor, namely reductions in IRS-1 associated PI3 kinase
activity culiminating in reductions in glucose transport into the muscle (Dresner, Laurent
et al. 1999; Savage, Petersen et al. 2007). The understanding of the cellular mechanisms
of free fatty acid mediated effects on insulin sensitivity at the liver are less clear, but free
fatty acids appear to stimulate gluconeogenesis, at least at supra-physiological
concentrations in subjects with T2D, but not following an overnight fast (Boden, Chen et
al. 2001).
1.3.3 The Effects ofGrowth Hormone on Renal Physiology
It has been known since the 1950's that growth hormone mediates glomerular
haemodynamics, when Ikkos reported increased effective renal plasma flow (ERPF) and
glomerular fdtration rate (GFR) in a group of patients with acromegaly (Ikkos,
Ljunggren et al. 1956). Increased urinary albumin excretion is a characteristic feature of
hypersomatotropic states such as acromegaly, while patients with growth hormone
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deficiency have reduced GFR and ERPF (Hoogenberg, Sluiter et al. 1993). In humans,
exogenous administration of recombinant human growth hormone leads to increases in
both GFR and ERPF (Hirschberg, Rabb et al. 1989) and administration of somatostatin
analogues, (which block growth hormone secretion), to patients with acromegaly leads
to reductions in GFR, ERPF and urinary albumin excretion rates (Dullaart, Meijer et al.
1992; Manelli, Bossoni et al. 2000).
It is unclear whether growth hormone's effects on renal physiology are due to a direct
effect on the kidney, or mediated via increases either in circulating or intra-renal
concentrations either of IGF-I or epidermal growth factor (EGF) (Flyvbjerg 2000). Very
detailed studies of the expression of growth hormone and its dependent peptides have
been performed in rodents (Flyvbjerg 2000). Flowever, the information pertaining to the
human kidney, particularly in healthy humans is, (for reasons which are perhaps
obvious!) very limited, but the available data indicate that there may be important
differences between species. For example, in the rat nephron, expression of IGF-I, but
not IGF-II has been demonstrated, in contrast to the human where there is no detectable
evidence of IGF-I transcription (in the form of IGF-I mRNA), but IGF-II mRNA can be
detected, predominantly localised to the perivascular regions (Chin and Bondy 1992).
Caution must therefore be exercised when extrapolating the findings from animal work
to humans, both in healthy animals and in experimental models of diseases such as
diabetes.
Most available evidence from healthy humans supports the hypothesis that GH exerts its
effects on renal haemodynamics secondary to an increase in circulating IGF-I, with
effects on GFR being delayed and only becoming apparent after 24hrs, concomitant with
a rise in IGF-I. i.e. growth hormone appears to affect GFR chronically rather than
acutely, which may reflect the temporal delay in the rise in circulating IGF-I
concentrations following commencement of exogenous growth hormone administration
(Hirschberg, Rabb et al. 1989).
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The expression of IGF binding protein-like proteins on the membrane of renal tubular
cells implies that, in addition to straightforward re-absorption and degradation by tubular
cells as a means of clearing IGF-I, that IGF-I, along with other growth factors may exert
a local effect within the tubular cells but as yet the details of these have not been
characterised (Flyvbjerg, Landau et al. 1995).
1.4. Insulin-Like Growth Factor - I
1.4.1 Historical Background
The insulin-like growth factors were first discovered in 1957; when Salmon and
Daughaday demonstrated that radio-labelled sulphur could be incorporated into
chondrocytes in vitro (Salmon and Daughaday 1957). They isolated two peptides of
molecular weight approximately 7 -kD and named them somatomedin 1 and 2. Further
work led to characterisation of their insulin-like actions when Froesch reported that the
addition of anti-insulin antibodies to serum did not completely ameliorate insulin like
activity (Froesch, Burgi et al. 1963). By 1972, the somatomedins were known to have
growth hormone dependent serum concentrations and stimulatory effects on DNA
synthesis and cell proliferation (Daughaday, Hall et al. 1972). Their metabolic actions,
in particular their insulin-like actions, resulted in them being re-named insulin-like
growth factors 1 and 2; IGF-I and IGF-II (Rinderknecht and Humbel 1976).
1.4.2 Structure and Regulation ofSecretion
The IGF-I gene is located on the long arm of chromosome 12 and encodes a basic
peptide 70 amino acids in length (Brissenden, Ullrich et al. 1984; Tricoli, Rail et al.
1984). The translated gene product, human IGF-I, has a molecular weight of
approximately 7 -kDa (Brissenden, Ullrich et al. 1984; Tricoli, Rail et al. 1984). It is
structurally very similar both to insulin and to IGF-II, sharing approximately 50 and
61% amino acid homology respectively with these family members (Rinderknecht and
Humbel 1978). In common with insulin, its secondary structure comprises A and B
chains held together by disulphide bonds. In addition, there is a C-peptide region of 12
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amino acids, which connects the A, and B chains, but despite there being a similar
region in the pro-insulin molecule, this region of IGF-I bears no homology to insulin
(Rinderknecht and Humbel 1978).
The secretion of IGF-I is predominantly growth hormone dependent and evidence of
IGF-I transcription can be demonstrated approximately 30 minutes following injection
of growth hormone into rats (Mathews, Norstedt et al. 1986). In humans, the majority of
circulating IGF-I is synthesised and secreted by the liver, following the binding of
growth hormone to its hepatic growth hormone receptor (Schwander, Hauri et al. 1983).
The expression of the hepatic growth hormone receptor is exquisitely sensitive to
concentrations of insulin within the portal circulation; thus low levels of portal insulin
lead to reduced expression of the hepatic growth hormone receptor and relative hepatic
resistance to growth hormone, which, in turn leads to reduced concentrations of
circulating IGF-I (Clayton, Holly et al. 1994). In addition to the liver, many other tissues
including muscle, kidney and the growth plate, express the growth hormone receptor,
and are capable of local IGF-I transcription and translation (D'Ercole, Stiles et al. 1984).
In humans, several authors have described an increase in the generation of IGF-I mRNA
in adipocytes following growth hormone stimulation in vitro (Doglio, Dani et al. 1987;
Gaskins, Kim et al. 1990).
1.4.3 Receptor binding and downstream signalling
IGF-I will bind to several receptors, including both the type one and type two IGF
receptors and the insulin receptor, in addition to hybrid and atypical IGF receptors
(Soos, Field et al. 1993). The type one IGF receptor is expressed widely in humans, with
liver being the notable exception (Caro, Poulos et al. 1988). It shares approximately
70% homology with the insulin receptor and binds both IGF-I and IGF-II with great
affinity (Massague and Czech 1982; Ullrich, Gray et al. 1986). The type 1 IGF receptor
will also bind insulin, but with considerably lower affinity (about 100 times) (Steele-
Perkins, Turner et al. 1988). In common with the insulin receptor, the type one IGF
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receptor comprises 4 subunits; 2 ligand binding (alpha) subunits which span the
membrane and 2 predominantly intracellular beta subunits which undergo tyrosine
kinase mediated autophosphorylation leading to activation of the intracellular signalling
cascade, which includes insulin receptor substrate 1 (IRS-1) (Siddle, Urso et al. 2001).
The intracellular signalling pathways of insulin and 1GF-I have many common elements
with both ultimately influencing gene expression (Siddle, Urso et al. 2001). Effects on
growth and metabolism are presumably exerted at this level. Effects on metabolism are
mainly effected via the PI3 kinase pathway, with effects on growth and differentiation
being effected via activation of the MAP kinase pathway (Shepherd, Nave et al. 1996). It
is currently not clear how cells distinguish between the 2 ligands (IGF-I and insulin) in
order for them to exert differential effects, given the seemingly identical signalling
pathways of the type one IGF, and insulin receptors (Siddle, Urso et al. 2001).
In contrast, the type 2 IGF receptor bears no similarity either to the type one IGF
receptor, or to the insulin receptor and binds IGF-II with high affinity, binding IGF-I
only weakly. It is identical to the mannose 6 phosphate receptor, which is responsible for
the intracellular targeting of lysosomal proteins (Morgan, Edman et al. 1987;
MacDonald, Pfeffer et al. 1988). It has been suggested that IGF-II may be integral to the
targeting of intracellular proteins in some way, or, alternatively that the type 2 IGF
receptor may simply be a way of clearing IGF-II from the circulation (Meyer, Eskelinen
et al. 2001).
Hybrid insulin/ type one IGF receptors have also been demonstrated in mammalian
tissues (Soos and Siddle 1989). Hybrid receptors are made up of one insulin receptor
dimer and one type 1 IGF receptor dimer, which are linked to form a tetramer (Feltz,
Swanson et al. 1988). Hybrid receptors bind both IGF-I and insulin with high affinity
but their physiological significance remains uncertain (Soos, Field et al. 1993).
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1.4.4 Biological Effects ofIGF-I
Given the almost universal expression of IGF-I, it has been difficult to distil out the
relative effects of circulating IGF-I concentrations as opposed to paracrine effects within
the target tissues secondary to local expression. The study of the phenotypes of a number
of animal models with selective mutations of individual components of either IGF-I or
its related peptides has given a degree of insight into these differential effects but the
picture is by no means complete.
1.4.4.i Growth
The phenotypes of mice null for the IGF-I gene, or the type 1 IGF receptor include
severe intrauterine growth retardation and early postnatal death (Baker, Liu et al. 1993).
The fragility of these null species has made more detailed postnatal physiological studies
impossible but more recently, sophisticated molecular techniques have permitted the
development of a mouse model which has selective reduction in hepatic IGF-I
expression with unaffected expression in all other tissues (the Liver IGF-I Deficient or
LID mouse) (Yakar, Liu et al. 1999). These animals have low circulating concentrations
of IGF-I, with increased growth hormone secretion, and have normal linear growth,
although with reduced bone mineral density and reductions in growth plate proliferation
(Yakar, Liu et al. 1999). Animals with a null mutation for the acid labile subunit (ALS)
of the ternary complex have a similar phenotype with reduced circulating IGF-I
concentrations but no increase in growth hormone secretion (Haluzik, Yakar et al. 2003).
It is only when animals have a double knockout for both ALS and the hepatic IGF-I
gene, resulting in further decreases in circulating IGF-I concentrations, that postnatal
linear growth is compromised (Haluzik, Yakar et al. 2003).
The human models of mutations in IGF-I and related peptides are extremely rare and do
not exhibit the tissue specificity afforded by the mouse models but they are in
themselves extremely informative. In the human, functional IGF-I generation appears
vital for both intrauterine and postnatal growth, with mutations either in the growth
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hormone receptor (Laron Syndrome), the IGF-I gene or the type 1 IGF receptor resulting
in IUGR and poor postnatal growth (Laron, Kowadlo-Silbergeld et al. 1980;
Walenkamp, Karperien et al. 2005; Walenkamp and Wit 2006). The copy number of the
IGF-I gene also has implications for altered growth potential; a child with a single copy
of the IGF-I gene has been reported with IUGR, postnatal growth failure and
hypoglycaemia, in contrast to a child who was born large for gestational age who
subsequently demonstrated rapid postnatal growth who was found to have 3 copies of
the IGF-I gene (Woods, Camacho-Hubner et al. 1996; Okubo, Siddle et al. 2003).
1.4.4.ii Metabolism
As its name suggests, IGF-I has insulin-like actions; following receptor binding there is
activation of its intracellular signalling cascade, which is almost identical to that of
insulin. IGF-I has direct actions on glucose metabolism and causes hypoglycaemia
approximately 30min after injection when administered to healthy volunteers (Guler,
Zapf et al. 1987). Detailed studies in healthy humans suggest that IGF-I administration
acutely suppresses both endogenous hepatic glucose production, and stimulates
peripheral glucose utilisation during a hyperinsulinaemic clamp, but has no effects on
lipolysis (Russell-Jones, Bates et al. 1995). Detailed studies of glucose metabolism in
the LID mouse suggest that these animals have reduced insulin sensitivity at the muscle,
but that their hepatic insulin sensitivity is unaffected indicating that IGF-I generated by
the liver acts peripherally at the muscle in an endocrine fashion to enhance insulin
sensitivity, but that there is no direct paracrine effect of IGF-I on insulin sensitivity at
the liver at least in this animal model (Yakar, Liu et al. 2001).
IGF-I also exerts anabolic effects on protein metabolism, and leads to reductions in
protein turnover and increases in lean body mass when administered to rats for 21 days
(Frick, Oscarsson et al. 2000). The anabolic effects of IGF-I have been confirmed in
humans using sophisticated physiological studies of amino acid turnover and have
- Page 16 -
shown to be independent of and of greater magnitude than, the actions of insulin
(Fryburg, Jahn et al. 1995).
In hypophysectomised rats, administration of IGF-I for 21 days leads to a reduction in
glucose uptake by adipocytes and an increase in glucose uptake by skeletal muscle cells,
along with a concomitant reduction in plasma insulin concentrations (Frick, Oscarsson et
al. 2000). The differences in glucose uptake between fat and muscle may be secondary
to the reduction in insulin concentrations, leading to reduced glucose uptake by the
exquisitely insulin sensitive adipocyte (Frick, Oscarsson et al. 2000). Currently,
although new details regarding the intracellular signalling of growth hormone, insulin
and IGF-I are being elucidated and reported, the finer details of intricate intracellular
cross-talk and subtle regulation between the 3 systems remains far from completely
understood.
1,4.4.iii Renal Physiology
As previously discussed, subjects with conditions of growth hormone excess such as
acromegaly have elevated glomerular filtration rate and effective renal plasma flow, in
conjunction with elevations in plasma IGF-I concentrations. Most authors concur that
the observed effects on renal haemodynamics following growth hormone treatment are
secondary to elevations in plasma IGF-I concentrations, both in healthy humans and in
rodents (Hirschberg and Kopple 1989; Hirschberg, Rabb et al. 1989; Flirschberg,
Brunori et al. 1993).
Administration of IGF-I to healthy volunteers, and to patients with chronic renal
impairment leads to increases in GFR and ERPF and so it would seem that circulating
concentrations of IGF-I are able to influence renal haemodynamics directly (Hirschberg
and Kopple 1989; Hirschberg, Brunori et al. 1993).
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1.5. The IGF Binding Proteins
The pool of IGF-I within the circulation is a dynamic resource, comprising 'free' or
bioactive IGF-I and IGF-I bound to binding proteins. Only a small proportion of IGF
circulates in its unbound or 'free' form, with the majority bound to one of the binding
proteins which serve to increase the half-life, facilitate transport and regulate the
bioactivity and tissue delivery of IGF peptides.
The IGF binding proteins are a family of soluble proteins which bind both IGF-I and
IGF-II with high affinity. So far 6 have been characterised to varying extents in humans
and there is around 80% sequence homology between species, particularly in the ligand
binding regions which are rich in cysteine residues (Firth and Baxter 2002). The pool of
IGF-I within the circulation is a dynamic resource, comprising 'free' or bioactive IGF-I
and IGF-I bound to binding proteins. All 6 binding proteins bind both IGF-I and IGF-II
with high affinity, with the possible exception of IGFBP-6, which has a much greater
affinity for IGF-II (Clemmons 1993). IGFBP-1 and IGFBP-3 are the most
comprehensively described of the IGFBPs in humans and will now be discussed in
further detail.
1.5.1 IGF Binding Protein 1
IGFBP-1 is a 30 -kDa non-glycosylated protein that binds both IGF-I and IGF-II with
high affinity. Binding to IGFBP-1 has an inhibitory effect on IGF-I action in vitro and
thus regulation of production of IGFBP-1 may serve to regulate the acute regulation of
bioavailable IGF-I (Clemmons, Busby et al. 1995). Acutely, IGFBP-1 production is
exquisitely sensitive to circulating insulin concentrations, which inhibits its production.
IGFBP-1 may function as an acute regulator of IGF-I bioavailibility, with suppression of
IGFBP-1 production by insulin (for example following a meal) leading to an increase in
bioavailable IGF-I to potentiate glucose uptake by target tissues (Clemmons, Busby et
al. 1995).
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1.5.2 IGF Binding Prote in 3
IGFBP-3 is the most abundant IGFBP in humans and binds approximately 75% of
circulating IGF-I (Martin and Baxter 1986). IGFBP-3 is a 266 amino acid protein, which
undergoes variable amounts of post-translational modification in the form ofN-linked
glycosylation at 3 potential sites, leading to a molecular weight which can vary between
30 and 56-kDa (Firth and Baxter 1995). IGFBP-3 can bind IGF-I alone, but the 2
predominantly coexist in a 150-kDa ternary complex with the acid labile subunit (ALS),
an 88-kDa glycoprotein (Baxter and Martin 1989). Incorporation of IGF-I into the
ternary complex extends its half-life from minutes to approximately 15 hours, thus
creating a relatively stable pool of IGF-I within the circulation (Baxter and Martin
1989). The synthesis of both IGFBP-3 and ALS appear to be predominantly regulated by
growth hormone and concentrations tend to be low in patients with hypopituitarism and
Laron dwarfism with some authors advocating its use as a clinical marker of growth
hormone deficient states (Thalange, Price et al. 1996). Administration of either IGF-I or
growth hormone to growth hormone deficient mice results in an increase in IGFBP-3
concentrations so it would seem that growth hormone may stimulate the hepatic
production of IGFBP-3 either via IGF-I, or that IGF-I may act independently to induce
transcription and translation of the IGFBP-3 gene (Camacho-Hubner, Clemmons et al.
1991).
IGFBP-3 is also subject to degradation by protease activity which provides a further
level of regulation of IGFBP-3 concentrations and hence IGF-I bioavailibility (Baxter,
Suikkari et al. 1993). IGFBP-3 protease activity was initially described in the serum of
pregnant women; proteolysis of IGFBP-3 leads to the formation of fragments that bind
IGF-I with reduced affinity, thus increasing the bioavailibility of IGF-I (Baxter, Suikkari
et al. 1993). IGFBP-3 proteases have not yet been fully characterised but are thought to
be serine, or metallo-proteases (Bunn and Fowlkes 2003; Fowlkes, Serra et al. 2004).
Increased activity of IGFBP-3 proteases has been described in type one diabetes and has
also been associated with certain malignancies and catabolic states (Lassarre, Duron et
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al. 2001). For example, prostate specific antigen stimulates the proteolysis of IGFBP-3,
leading to a reduced binding affinity for IGF-I. It is suggested that this leads to increased
bioavailibility of IGF-I, with potential enhancement of its biological effects (Bunn and
Fowlkes 2003).
Thus regulation of IGFBP-3 synthesis and of its subsequent proteolysis under certain
conditions permits a dynamic regulation of bioavailable IGF-I but the exact nature or
significance of the mechanisms which induce and regulate this remain uncertain.
1.5.3 Other Members ofthe IGFBP Super family
Whilst IGFBP-1 and IGFBP-3 are the best characterised of the IGF binding proteins,
there are other binding proteins which have been isolated as a result of their strong
interaction with ligand (i.e. IGF-I and IGF-II). However, it has more recently become
apparent that the IGFBPs are part of a super family of proteins sharing sequence
homology and include a number of so-called IGFBP related peptides (IGFBPrps) which
have been characterised from biological systems distinct than the IGF-I axis, and
retrospectively been discovered to have significant sequence homology to the IGF
binding proteins, particularly within the N terminal cysteine-rich region,
comprehensively reviewed by Hwa and Rosenfeld (Hwa, Oh et al. 1999).
1.5.3.i IGF Binding Protein 2
The IGFBP-2 gene is located on chromosome 2, encoding a protein of molecular weight
approximately 34 -kDa and is highly expressed in fetal CNS tissues. At least in the
mouse model, knockout of the IGFBP-2 gene has little phenotypic effect.
1,5.3.ii IGF Binding Protein 4
The IGFBP-4 gene is located on chromosome 17, and encodes a 237 amino acid protein
which is expressed predominantly in liver. The biological role of IGFBP-4 seems
predominantly in the regulation of cell proliferation at the growth plate.
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1.5.3.iii IGF Binding Protein 5
The IGFBP-5 gene is located on chromosome 5, and encodes a 252 amino acid protein
which is expressed predominantly in kidney. IGFBP-5 appears to either enhance or
inhibit IGF actions dependent on circumstances and appears particularly important in the
regulation of IGF-I action in atretic ovarian follicles and also in bone.
1.5.3.iv IGF Binding Protein 6
The IGFBP-6 gene is located on chromosome 12, and encodes a 216 amino acid protein
and binds IGF-II with greater affinity than it does IGF-1. It is present in relatively high
levels in cerebrospinal fluids.
1.5.4 The IGFBP Related Peptides
The IGFBPrps have distinct structural homology to the IGF binding proteins but bind
ligand (IGF-I and IGF-II) at least in vitro, but with much weaker affinity than IGFBPs 1
to 6. To date, up to 9 have been described. They have predominantly isolated from
tumour cell lines and have a number of proposed biological functions including the
regulation of IGF mediated cellular proliferation and suppression of tumours and
vascular disease (Hwa, Oh et al. 1999).
1.5.5 Quantification ofIGF-I
Conventional laboratory immunoassays for IGF-I quantify total IGF-I, both free IGF-I
and IGF-I that is bound to binding proteins, including that incorporated into the ternary
complex with ALS. Conventional immunoassays have an initial acidification step during
which IGF-I is stripped from the binding proteins before quantification of total (i.e.
bound and unbound) IGF-I.
Total IGF-I determination, while useful, gives no information regarding the portion of
IGF-I that is unbound and thus readily bio available. The molar ratio of IGF-I to IGFBP-
3 has been used as a surrogate for bio available IGF-I, but as it does not take into
consideration any of the other binding proteins it is, at best a crude proxy.
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Jan Frystyk and Hans Orskov, from Aarhus University in Denmark, have developed a
reliable assay for free IGF-I, but it is currently not commercially available (Frystyk,
Hussain et al. 1997). Use of this assay provides valuable information regarding
bioavailable IGF-I and has been useful in evaluating subtle variation in the growth
hormone - IGF-I axis and their relation to observed biological effects (Frystyk, Hussain
et al. 1997).
1.6. The Growth Hormone - IGF-I Axis in Type 1 Diabetes
1.6.1 Regulation
1.6.1.i Total IGF-I
Concentrations of circulating IGF-I are low in people with type one diabetes (Edge,
Dunger et al. 1990). Circulating IGF-I is predominantly derived from the liver and its
release is stimulated by growth hormone (Melmed and Kleinberg 2003). In the non-
diabetic, insulin is released from the pancreas directly into the portal circulation and
subsequently approximately 70% is cleared as a result of first pass metabolism (Eaton,
Friedman et al. 1984). Concentrations of insulin within the portal circulation correlate
directly with the expression of the hepatic growth hormone receptor (GHR) and thus in
Type 1 Diabetes, where insulin concentrations within the portal circulation are low, the
expression of the hepatic GHR is reduced (Shishko, Dreval et al. 1994). In humans this
has been confirmed by the low circulating levels of growth hormone binding protein
(GHBP); the circulating portion of the hepatic GHR in Type 1 Diabetes (Cheetham,
Taylor et al. 1994; Hanaire-Broutin, Sallerin-Caute et al. 1996). The reduced expression
of the hepatic GHR leads to a reduction in hepatic IGF-I generation and low circulating
levels of IGF-I (Clayton, Holly et al. 1994).
Intraperitoneal administration of insulin in Type 1 Diabetes partially restores the
parameters of the growth hormone - IGF-I axis to normal (Hanaire-Broutin, Sallerin-
Caute et al. 1996) and when insulin replacement in Type 1 Diabetes is administered
directly into the portal circulation, the aberrations of growth hormone and its dependent
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peptides are restored to normal (Shishko, Dreval et al. 1994). Currently, portal insulin
administration is not a viable therapeutic option in Type 1 Diabetes, however, with the
future development of implantable insulin pump devices, future methods of insulin
replacement may be much more physiological, not just in terms of dose delivered, but in
the anatomical site of delivery.
1.6.1 .ii Growth Hormone Hypersecretion
Low concentrations of circulating IGF-I results in a failure of the negative feedback
mechanism at the pituitary (Figure 3), resulting in growth hormone hypersecretion that is
primarily nocturnal (Edge, Dunger et al. 1990). There is both increased basal growth
hormone secretion as well as increased frequency and amplitude of overnight growth
hormone pulses when compared to non-diabetic controls matched for age, sex and
puberty stage (Edge, Dunger et al. 1990).
1.6.1 .iii IGF Binding Proteins and Free IGF-I
In Type 1 Diabetes, concentrations of IGFBP-1 are increased secondary to low
concentrations of insulin within the portal circulation and consequent reduced
suppression of hepatic generation of IGFBP-1 (Holly, Dunger et al. 1990; Batch, Baxter
et al. 1991). IGFBP-1 has a predominantly inhibitory effect on the actions of IGF-I, the
increased amounts produced in young people with Type 1 Diabetes are likely to
compound the already low total IGF-I concentrations resulting in further reductions in
bio available IGF-I (Holly, Smith et al. 1989; Shishko, Dreval et al. 1994).
1.6.2 Metabolic Effects
1.6.2.1 Insulin sensitivity
During normal puberty, there is a rise in insulin resistance, which is maximal during
mid-puberty and that subsequently falls to pre-pubertal levels during adulthood (Caprio,
Cline et al. 1994). This physiological rise in insulin resistance during puberty is
accentuated in T1D, with adolescents with T1D being more insulin resistant than control
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children matched for age, sex and puberty stage, as determined using hyperinsulinaemic
euglycaemic clamp techniques (Amiel, Sherwin et al. 1986).
The exacerbation of the normal pubertal insulin resistance seen in Type 1 Diabetes may
be explained by the aberrant regulation of the growth hormone - IGF-I axis described
above. Low levels of IGF-I lead to growth hormone hypersecretion, which has a
synergistic effect on glucose metabolism; with reduced amounts of bio available IGF-I













Figure 3: The Growth Hormone - IGF-IAxis in Type One Diabetes
In young people with Type 1 Diabetes; low concentrations of insulin within the portal
circulation result in reduced hepatic IGF-I generation with consequent growth hormone
hypersecretion. This leads to exacerbates pubertal insulin resistance either by direct or
indirect mechanisms.
As discussed earlier in this chapter, growth hormone has direct effects on insulin
sensitivity and causes a reduction in insulin sensitivity that is maximal around 5 to 6
hours after a growth hormone pulse (Rizza, Mandarino et al. 1982). In Type 1 Diabetes
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this manifests clinically as the 'dawn phenomenon'. Overnight growth hormone
secretion is maximal in the early hours of the night (at around OlOOh) and this results in
increased insulin resistance, with an increase in insulin requirements during the late part
of the night with resultant fasting hyperglycaemia (Edge, Dunger et al. 1990). Practically
speaking, in terms ofmanagement this can lead to problems as conventional insulin
preparations have maximal effect in the early hours of the night, when insulin
requirements are at their lowest, but their actions are waning as insulin requirements rise
during the latter part of the night and thus increasing the evening dose of insulin in an
attempt to control morning hyperglycaemia may result in unacceptable hypoglycaemia
during the early part of the night and this may be compounded if soluble insulin is used
in conjunction with Neutral Protamine Hagedorm (NPH) insulin. The problem with
nocturnal hypoglycaemia my be partially resolved if soluble insulin is replaced with a
rapid acting analogue such as insulin lispro (Ford-Adams, Murphy et al. 2003).
1.6.2.ii Lipolysis
As well as having direct effects on insulin sensitivity, growth hormone has indirect
effects on insulin sensitivity that are mediated via its effects on lipolysis. Growth
hormone acts to stimulate lipolysis with subsequent release of free fatty acids (Arslanian
and Kalhan 1994; Piatti, Monti et al. 1999). Increased concentrations of circulating free
fatty acids contribute to reductions in insulin sensitivity via the competitive inhibition of
GLUT 4 mediated glucose uptake at cell membranes (Shulman 2000). Increased rates of
lipolysis overnight have been demonstrated in young people with Type 1 Diabetes, and
while this may be secondary to suboptimal insulinisation overnight, growth hormone
hypersecretion is likely to be a contributory factor (Hagstrom-Toft, Bolinder et al.
1997).
1.6.3 Summary
In summary, the growth hormone - IGF-I axis is aberrantly regulated in young people
with Type 1 Diabetes. The peripheral administration of insulin leads to reduced hepatic
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IGF-I generation and thus to reduced circulating concentrations of IGF-I which in turn
leads to growth hormone hypersecretion due to reduced negative feedback at the
pituitary. The low concentrations of IGF-I are compounded by increased levels of
IGFBP-1 (the main inhibitory binding protein for IGF-I) resulting in a further reduction
in IGF-I bio availability. Low concentrations of IGF-I and growth hormone
hypersecretion may compound difficulties with management, by causing insulin
resistance, both directly and indirectly, by the stimulation of lipolysis. Administration of
insulin directly into the portal circulation has been shown to restore the parameters of
the growth hormone - IGF-I axis to normal in Type 1 Diabetes; however this is not
currently a reasonable therapeutic option.
1.7. Nephropathy in Diabetes
1.7.1 Incidence and Implications
Diabetes (types one and two) is the most common cause of end stage renal failure in the
developed world and accounts for approximately half of all cases, with a considerable
associated economic burden [http://www.usrds.org/adr_2004.htm]. (US Renal Data
System, 2004). The cumulative incidence of nephropathy increases progressively from
diagnosis but plateaus at around 40%, which may indicate that certain individuals are
vulnerable to the development of nephropathy while others are protected, no matter how
bad their diabetes control (Hovind, Tarnow et al. 2004). Investigation of current
candidate genetic polymorphisms is underway in an attempt to identify those potentially
at risk of nephropathy and target them for early and aggressive intervention
(Chowdhury, Dronsfield et al. 1996; Chowdhury, Dyer et al. 1998).
1.7.2 Natural history
The herald sign of renal disease in type one diabetes is glomerular hyperfiltration; first
noted by Cambier in 1934 when he reported that subjects with newly diagnosed Type 1
Diabetes had greater inulin clearances than controls (Cambier 1934). Glomerular
hyperfiltration has subsequently been confirmed by numerous authors (Ditzel and
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Schwartz 1967; Mogensen 1971). The period of hyperfiltration is transient, and is
associated with increased renal size on ultrasound (Christiansen, Gammelgaard et al.
1981; Mogensen, Christensen et al. 1990). It is unclear what mechanism drives the
hyperfiltration and numerous candidates have been proposed, including hyperglycaemia.
Hyperfiltration appears to affect only 30 to 40% of young people with Type 1 Diabetes
and intensification of insulin treatment with reduction in hyperglycaemia leads to a
decline in GFR over successive weeks (Christiansen, Giese et al. 1988). It is possible
that glomerular hyperfiltration may be an early manifestation of an individual's
predisposition to hyperglycaemic renal insult.
Longitudinal studies have demonstrated that early hyperfiltration predicts risk of
subsequent nephropathy (Rudberg, Persson et al. 1992). Recent work from the Oxford
cohort of young people with type one diabetes (ORPS) confirms this, with those who
subsequently go on to develop microalbuminuria having significantly higher GFR five
years from diagnosis than those who do not develop MA, independently of HbAlc and
duration of diabetes (Amin, Turner et al. 2005).
Around 18 to 24 months from diagnosis, glomerular lesions can be seen on biopsy, but
urinary albumin excretion rate (AER) remains within the normal range (< 25mg / 24
hrs). Lesions are characterised by thickening of the glomerular basement membrane,
coupled with expansion of the mesangial matrix (Osterby, Bangstad et al. 1996).
The first clinical manifestation of diabetic nephropathy is microalbuminuria (MA), a
persistent elevation in AER which is incipient and in the range 30 to 300 mg / 24 hr
which subsequently climbs into the frankly nephrotic range (AER >300mg/24hrs).
Urinary albumin excretion varies greatly from day to day within individuals, being
increased following exercise and brief periods of very poor metabolic control (Cohen,
Close et al. 1987). Because of this, MA should not be diagnosed unless it has been
present in 2 out of 3 timed urine collections on at least 2 separate occasions during a 6
month period (Schultz, Amin et al. 2002). Microalbuminuria is rare before puberty, but
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thereafter its incidence increases resolutely and is often associated with abnormalities in
control of blood pressure; initially with loss of normal nocturnal dipping in systolic
blood pressure (only apparent with 24 hour ambulatory blood pressure monitoring), with
subsequent frank hypertension (Darcan, Goksen et al. 2006). In addition to
intensification of insulin therapy and optimisation of glycaemic control, therapy with an
angiotensin converting enzyme (ACE) inhibitor confers renal protection at this stage
(Laffel, McGill et al. 1995).
An albumin excretion rate of 300mg / 24hrs, defines frank nephropathy and is
accompanied by a progressive decline in GFR exacerbated by hypertension (Rudberg
and Osterby 1997). Subsequent end stage renal failure with need for dialysis and renal
transplantation is almost inevitable in those with nephropathy after 20 to 30 years
diabetes duration.
1.7.3 Riskfactors
The main risk factor for the development of diabetic kidney disease is poor control; risk
of nephropathy has been shown to correlate directly with HbAlc in many studies
(Rudberg and Dahlquist 1996). Intervention has likewise been shown to reduce
nephropathy risk; the landmark Diabetes Control and Complications Trial (DCCT)
demonstrated that aggressive diabetes management with intensive insulin therapy to
improve glycaemic control and reduce HbAlc resulted in significantly lower risk of
nephropathy development in a cohort of adolescents with type one diabetes (1994).
Although the importance of glycaemic control as a primary determinant of
complications risk cannot be ignored, there are other factors that appear to be important
in determining risk of nephropathy. Diabetes duration, angiotensin converting enzyme
genotype, hypertension, smoking, family history of hypertension and female sex may all
confer risk of nephropathy, independently ofHbAlc (Rudberg and Dahlquist 1996). The
Oxford Regional Prospective Study (ORPS) has followed a large cohort of young people
with type one diabetes followed longitudinally from diagnosis, with annual
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determination ofHbAlc, albumin creatinine ration (ACR), sex hormone binding
globulin and parameters of the GH/IGF-I axis (Schultz, Konopelska-Bahu et al. 1999).
Cases with microalbuminuria (MA) were then compared with MA negative controls
matched for age, sex, and duration of diabetes. Independently ofHbAlc, female sex and
puberty stage were independently associated with MA (Schultz, Konopelska-Bahu et al.
1999). Additionally, in the females, MA risk was associated with a lower sex hormone
binding globulin (ie increased free androgen index) (Amin, Schultz et al. 2003). Further
analysis within the same cohort revealed that subjects with MA had a significantly lower
free IGF-I concentration than MA negative controls matched for age, sex, puberty stage
and duration of diabetes, independently ofHbAlc (Amin, Schultz et al. 2003).
1.7.4 The role ofGrowth Hormone and IGF-I in Diabetic
Nephropathy
Historically it was noted that patients with both diabetes and growth hormone deficiency
were protected against the microvascular complications of diabetes; retinopathy and
nephropathy. Indeed, hypophysectomy was at one time used in the treatment of severe
retinopathy, a treatment that has now (thankfully!) been obviated by the development of
laser ablation of neovascularisation. In addition, patients with acromegaly exhibit
glomerular hyperfiltration and increased urinary albumin excretion, particularly during
exercise (Hoogenberg, Sluiter et al. 1993; Manelli, Bossoni et al. 2000). Subjects with
Type 1 Diabetes and glomerular hyperfiltration (GFR>130 ml/min/1.73m2) have higher
overnight growth hormone secretion than those with normofiltration (Blankestijn, Derkx
et al. 1993). More recently, young adults with MA from a large longitudinal cohort study
have been shown to have increased overnight growth hormone secretion than those
without MA, in addition to lower concentrations of IGF-I (Amin, Williams et al. 2005).
In Type 1 Diabetes, hyperfiltration precedes the development ofMA and the subsequent
decline in GFR and frank nephropathy. Hyperfiltration soon after the diagnosis of Type
1 Diabetes may also predict MA (Amin, Turner et al. 2005; Steinke, Sinaiko et al. 2005).
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Thus growth hormone hypersecretion could have a role in the pathogenesis of early
diabetic nephropathy. Abnormalities of the growth hormone - IGF-I axis similar to
those seen in humans are seen in a mouse model of diabetes in which treatment with a
specific growth hormone antagonist leads to reductions in GFR and urinary albumin
excretion, secondary to a reduction in renal expression of IGF-I (Flyvbjerg, Bennett et
al. 1999).
Although there is hepatic resistance to growth hormone, the integrity ofGHR expression
in peripheral tissues such as the kidney remains intact (Flyvbjerg 2000). In the face of
exaggerated growth hormone secretion, increased paracrine production of IGF-I in
peripheral tissues occurs (Segev, Landau et al. 1997). Studies in humans have
suggested that subjects with MA have higher urinary IGF-I than controls withoutMA,
despite the fact that circulating serum levels of free IGF-I are lower in patients with MA
than their matched controls without MA (Cummings, Sochett et al. 1998; Amin, Ong et
al. 2001). However, urinary data need to be interpreted with caution as urinary
concentrations of peptide hormones depend not only on local concentrations within the
kidney but also on tubular function and have to be viewed with a degree of scepticism in
the light of a kidney which is leaking albumin, a much larger protein (Hourd, Edge et al.
1991). Despite this, there is mounting evidence from rodent models of diabetes that
nephropathy correlates directly with IGF-I expression within the kidney (Flyvbjerg
2000).
1.8. The Growth Hormone - IGF-I Axis in Type 1 Diabetes:
Potential Strategies for Manipulation
The abnormalities of the growth hormone - IGF-I axis in type one diabetes may lead to
increased insulin resistance, increased lipolysis and contribute to the development of the
complications of diabetes around puberty. Manipulation of the growth hormone - IGF-I
axis in an attempt to restore more normative physiology may provide an additional
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strategy by which to improve insulin sensitivity and reduce the risk of the microvascular
complications. There are a number of potential ways of approaching this.
1.8.1 Specific Growth Hormone Receptor Blockade
1.8.1. i Specific Growth Hormone antagonists
Recombinant DNA technology has facilitated generation of powerful growth hormone
analogues which bind to the growth hormone receptor with high affinity, but do not
activate downstream signalling; growth hormone antagonists (GHA). B2036-PEG
(Pegvisomant, Somavert, Pharmacia) is a GHA developed for use in refractory
acromegaly and incorporates mutations of 9 amino acids in the native human growth
hormone molecule. The addition of a polyethylene glycol moiety (pegylation) increases
the circulating half-life of the molecule to over 2 days and also reduces its
immunogenicity. B2036-PEG binds to the GHR with greater affinity than does the
native human growth hormone molecule, but does not induce the functional
conformational change within the receptor, which is required for downstream signalling
(Figure 4) (Thorner, Strasburger et al. 1999).
Despite binding to the receptor with greater affinity, much higher concentrations of
B2036-PEG are required for reductions in IGF-I both in healthy control subjects and in
subjects with acromegaly (Thorner, Strasburger et al. 1999; Trainer, Drake et al. 2000).
Detailed studies of receptor binding indicate that modification of the molecule by
Pegylation in order to reduce immunogenicity and prolong half life may lead to a
reduced affinity for the receptor dimer (Ross, Leung et al. 2001).
1.8.1 .ii B2036-PEG: preliminary data
Phase 1 studies of B2036-PEG administration to healthy males demonstrated that a
single dose of lmg/kg was well tolerated, and led to reductions in IGF-I concentrations
by approximately 50% after 5 days (Thomer, Strasburger et al. 1999). In this study, the
authors reported that there was no increase in endogenous growth hormone secretion
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following B2036-PEG administration, and were careful to use assays for which there
was no cross reactivity between endogenous growth hormone and B2036-PEG by
(Thorner, Strasburger et al. 1999). It is likely that if conventional ELISA kits
incorporating polyclonal antibodies are used, that there would be cross reactivity
between endogenous growth hormone and the B2036-PEG molecule and the
manufacturers (Pfizer) recommend that in acromegaly, IGF-I concentrations, rather than
quantification of growth hormone is used for monitoring and dose titration.
Cell Membrane
A: Human Growth Hormone Receptor in
unoccupied state
Cell Membrane
B: Bound to human growth hormone (hGH)
Conformational change leads to activation of
downstream signalling pathways
Cell Membrane
C: Bound to Somavert (GHA).
There is avid binding, but no conformational
change and thus no signalling
Figure 4: The Human Growth Hormone Receptor
Effects ofbinding ofnatural ligand (hGH) and specific growth hormone antagonist
(GHA).
1.8.1 .iii B2036-PEG: studies in acromegaly
Studies in patients with acromegaly have shown the GHA B2036-PEG, Somavert
(Pharmacia Corporation) to effectively block the growth hormone receptor and reduce
concentrations of circulating IGF-I (dose 5 to 20 mg) (Trainer, Drake et al. 2000). The
drug is well tolerated and has few side effects (Trainer, Drake et al. 2000) and may
enhance insulin sensitivity, in contrast to the somatostatin analogue, octreotide, which
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has unpleasant side effects and may exacerbate insulin resistance (Rose and Clemmons
2002; Drake, Rowles et al. 2003). Acromegaly is characterised by reductions in total
cholesterol and LDL concentrations which are reversed by treatment with B2036-PEG in
conjunction with reductions in fasting insulin concentrations (Parkinson, Drake et al.
2002).
1.8.1 .iv Growth hormone blockade in animal models of diabetes
An experimental model of Type 1 Diabetes in mice has abnormalities of the growth
hormone - IGF-I axis similar to those seen in humans (Landau, Domene et al. 1998).
Administration of a GHA to mice with nephropathy leads to a reduction in renal
expression of IGF-I, renal size, GFR, ERPF and urinary albumin excretion rates
(Flyvbjerg, Bennett et al. 1999; van Neck, Dits et al. 2000). Thus far, no studies of the
effect ofGHAs on insulin sensitivity, renal physiology or tubular protein leak have been
performed in humans.
Selective blockade of the actions of growth hormone in young people with type one
diabetes may lead to improvements in insulin sensitivity and subsequently to reductions
in insulin requirements. In addition, blockade of the growth hormone receptor in the
kidney may afford renal protection and provide an alternative therapeutic strategy in this
vulnerable population.
1.8.2 IGF-IAdministration
1.8.2.i rhIGF-I therapy in humans with Type 1 Diabetes
rhIGF-I has been explored as an adjunctive therapy and the results of previously
published studies are summarised in Table 1 (Thrailkill KM FAU - Quattrin, Quattrin T
FAU - Baker et al.; Cheetham, Holly et al. 1995; Acerini, Patton et al. 1997; Carroll,
Umpleby et al. 1997; Cheetham, Connors et al. 1997; Quattrin, Thrailkill et al. 1997;
Acerini, Harris et al. 1998; Crowne, Samra et al. 1998; Quattrin, Thrailkill et al. 2001;
Simpson, Jackson et al. 2004). Administration of recombinant human IGF-I (rhIGF-I) to
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young adults with Type 1 Diabetes results in suppression of overnight growth hormone
secretion (Acerini, Harris et al. 1998). Detailed physiological studies of the
administration of exogenous rhIGF-1 (40mcg/kg/day) to adolescents with Type 1
Diabetes demonstrated reductions in overnight insulin requirements for euglycaemia, in
conjunction with reductions in overnight plasma insulin concentrations and increased
IGFBP-1 concentrations (Cheetham, Jones et al. 1993; Cheetham, Clayton et al. 1994).
Hyperinsulinaemic euglycaemic clamp studies using cold isotopes to model glucose
turnover revealed an increase in insulin sensitivity during the clamp following 1GF-I
administration, which appeared to be predominantly secondary to an effect on hepatic
glucose production (Acerini, Harris et al. 1998).
Longer-term clinical trials of adjunctive therapy with rhIGF-I were also carried out in
young people with Type 1 Diabetes. A randomised, double-blind placebo-controlled trial
of IGF-I at a dose of 40mcg/kg/day for 6 months reported a reduction in HbAlc after 3
months but no change in overall daily insulin requirement and the improvement in
HbAlc did not persist until the end of the trial which may reflect concordance issues
(Acerini, Patton et al. 1997). Importantly, at this physiological replacement dose of IGF-
I, there were no serious adverse events reported and the risk of hypoglycaemia was not
greater in the IGF-I treated group over the control group.
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11 40 24 hours
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lipid metabolism.
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1.8.2.ii rhIGF-I therapy in humans with T2DM
Adjunctive therapy with rhIGF-I has been studied in subjects with T2D by a number of
groups and details are summarised in Table 2 (Zenobi, Jaeggi-Groisman et al. 1992;
Schalch, Turman et al. 1993; Jabri, Schalch et al. 1994; Moses, Young et al. 1996; Cusi
and DeFronzo 2000). Doses administered ranged between 160 and 300 mcg/kg/day
(much greater than the doses used in the Type 1 Diabetes population) and exposure was
generally restricted to short-term (5 to 7 days) with physiological evaluation of insulin
sensitivity before and after exposure, but two groups have reported exposure for 6
weeks. With only one exception (Young and Clemmons 1994), authors report
improvements in insulin sensitivity, fasting glucose and response to oral glucose load
and more detailed physiological studies suggest an effect both on hepatic and peripheral
insulin sensitivity (Dunger, Yuen et al. 2004).
1.8.2.iii Safety issues
The development of unbound rhIGF-I as a potential therapeutic option in Type 1
Diabetes was discontinued due to concerns about the role of IGF-I in the microvascular
complications ofType 1 Diabetes and also due to dose-related side effects. Large IGF-I
doses (above 80 pg/kg/day) have been associated with a dose-dependent increase in side
effects, including oedema, jaw pain, arthralgia, and early worsening of retinopathy
(Quattrin, Thrailkill et al. 2001). Concern regarding the association of IGF-I, particularly
with retinopathy resulted in it being withdrawn from development as a potential therapy
in either type 1 or type 2 diabetes.
More recently, rhIGF-1 has been complexed to rhIGFBP-3, its natural carrier protein
(Mecasermin rinfabate, IPLEX™) in an attempt to prolong half-life and reduce the risk
of short-term peaks of free IGF-I. The combination of rhIGF-I with its natural binding
protein, rhIGFBP-3 may allow the efficacy of rhIGF-I to be realised without the
associated toxicity.
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6 240 5 days
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(Jabri, Schalch et al.
1994)
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6 160-300 4 days
Increased IGFBP-1, reductions
in IGFBP-3, with reduced area
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12 200 6 weeks
Decreased FIbAlc and increased
fasting insulin sensitivity.





8 160 7 days
Increased fasting insulin
sensitivity. Incraeased hepatic and
peripheral insulin sensitivity as
determined by hyperinsulinaemic
clamp studies.
1.8.2.iv rhIGF-I/rhIGFBP-3 complex: Mecasermin Rinfabate
rhIGF-I/rhIGFBP-3 complex (product name IPLEX ™, generic name Mecasermin
rinfabate, previously marketed as Somatokine) is a recombinant protein complex of IGF-
I and IGFBP-3 combined in equimolar proportions. It currently does not carry a license
for any therapeutic intervention. In animal studies, Mecasermin rinfabate displays
metabolic and anabolic actions similar to those observed when rhIGF-I is administered
alone (Adams, Moore et al. 1995; Bagi, van der Meulen et al. 1995). The ability of
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Mecasermin rinfabate to form a ternary complex with ALS (acid labile subunit) provides
a mechanism to maintain rhIGF-1 in a bound form in the circulation, thereby prolonging
its half-life and preventing the undesirable acute pharmacological effects that have been
observed following the administration of rhIGF-I alone (Adams, Moore et al. 1995).
Mecasermin rinfabate is produced by two strains of E. coli, one producing IGF-I and the
other, IGFBP-3. The two proteins then undergo a purification process and are combined
into a complex in equimolar proportions. At near neutral pH, the dissociation constant is
approximately 50 pM. Mecasermin rinfabate (marketed as IPLEX™) was developed by
Insmed Incorporated (PO box 2400, Glen Allen, VA 23058, USA) in the hope that it
would provide a more stable pool of circulating IGF-I within the circulation, potentially
improving the pharmacokinetic profile, and reducing the incidence of significant side
effects (Norman 2003).
Mecasermin rinfabate has been administered by subcutaneous injection once daily in
doses of between O.lmg/kg/day up to 2 mg/kg/day, depending on the indication [lmg
Mecasermin rinfabate equates to approximately 0.2mg of rhIGF-1], Once dissociated
from IGFBP-3, the rhIGF-I derived from Mecasermin rinfabate should bind to receptors
in an identical fashion to endogenous IGF-I, with indistinguishable biological effects.
In vitro animal studies demonstrated that the rhIGF-I/rhIGFBP-3 complex mimics the
physiological effects of IGF-I with a longer half-life (Sanders, Moore et al. 1997). In
animal studies the the rhIGF-I/rhIGFBP-3 complex has biological effects similar to or
enhanced when compared to IGF-I alone (Bagi, Brommage et al. 1994; Adams, Moore
et al. 1995; Bagi, van der Meulen et al. 1995; Bagi, DeLeon et al. 1995). On entering the
circulation the the rhIGF-I/rhIGFBP-3 complex binds to ALS to form the ternary
complex that forms the natural reservoir for circulating IGF-I. These preliminary
experimental studies were followed by Phase 1 and 2 clinical trials, which demonstrated
its safety and efficacy in adult healthy volunteers and subjects with type 1 and 2 diabetes
mellitus, patients recovering from osteoporotic hip fracture and children with Growth
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Hormone Insensitivity Syndrome (GHIS) (Clemmons, Moses et al. 2000; Boonen,
Rosen et al. 2002; Saukkonen, Amin et al. 2004; Clemmons, Moses et al. 2005;
Saukkonen, Shojaee-Moradie et al. 2006; Williams, Yuen et al. 2006; Clemmons, Sleevi
et al. 2007).
The dose ofMecasermin rinfabate has been titrated according to the individual subject,
but in most cases, the manufacturers recommend a starting dose of 0.5mg/kg/day, to be
titrated upwards in 0.5mg/kg/day increments, to a recommended maximum of
2mg/kg/day. In GHIS, the dose can be titrated to maintain IGF-I concentrations of the
order of +2 standard deviation scores for age, based on plasma IGF-I concentration
taken approximately 18 hours following a dose (Camacho-Hubner, Underwood et al.
2006). Injections should be given at approximately the same time every day, but can be
given either morning or evening, whichever is more convenient for the individual.
Once within the circulation, the rhIGF-I from the complex can form a ternary complex
with IGFBP-3 and Acid labile subunit (ALS) and is subsequently cleared from the
circulation by the same means as native IGF-I. Most studies reporting the administration
ofMecasermin rinfabate to humans report dose dependent increases in IGF-I, but with
less marked rises in IGFBP-3 (Clemmons, Moses et al. 2000; Clemmons, Moses et al.
2005; Saukkonen, Shojaee-Moradie et al. 2006; Clemmons, Sleevi et al. 2007). This has
led to speculation concerning possible proteolytic degradation of the non-glycosylated
form of the recombinant IGFBP-3. Endogenous IGFBP-3 is subject to degradation by
protease activity which provides a further level of regulation both of IGFBP-3
concentrations and functional capacity, and hence IGF-I bioavailibility (Baxter, Suikkari
et al. 1993). IGFBP-3 protease activity was initially described in the serum of pregnant
women; proteolysis of IGFBP-3 leads to the formation of fragments that bind IGF-I with
reduced affinity, thus increasing the bioavailibility of IGF-I (Baxter, Suikkari et al.
1993). IGFBP-3 proteases have not yet been fully characterised but are thought to be
serine, or metallo-proteases (Bunn and Fowlkes 2003; Fowlkes, Serra et al. 2004). Thus
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regulation of IGFBP-3 synthesis and of its subsequent proteolysis under certain
conditions permits a dynamic regulation of bio available IGF-I but the exact nature of its
significance or the mechanisms which induce proteolysis remain uncertain.
Work by Clemmons et al using immunoblotting techniques (Clemmons, Sleevi et al.
2005) suggests that, following administration Mecasermin rinfabate (containing the
recombinant form of IGFBP-3), the non-glycosylated protein is preferentially degraded
by plasma proteases, preferentially leaving the native glycosylated form of the protein.
1.8.3 Suppression ofgrowth hormone secretion
1.8.3.i Somatostatin and its analogues
Suppression of endogenous growth hormone secretion using the long acting
somatostatin analogue octreotide has been reported to reduce insulin requirements by up
to 50% in several clinical trials (Navascues, Gil et al. 1988; Kirkegaard, Norgaard et al.
1990; Orskov, Moller et al. 1996). However, benefits were limited by the development
of unacceptable side effects such as hypoglycaemia and gastrointestinal upset, which
occur as a result of somatostatin's ubiquitous effects on hormone secretion.
1.8.3 .ii Pirenzepine
Short-term clinical studies using the anti-cholinergic agent pirenzepine have also shown
effective suppression of growth hormone secretion with improvements in insulin
sensitivity (Martina, Maccario et al. 1989; Atiea, Asian et al. 1990; Aman, Kroon et al.
1996). Improvements in insulin sensitivity appeared to be mediated via an effect on
lipolysis (Halldin, Brismar et al. 2002). However, the short half-life of pirenzipine
limited its efficacy and attempts to prolong the half-life resulted in an exacerbation of
side effects, making it an unsuitable agent for long-term therapy (Krassowski, Szulc et
al. 1993).
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1.8.4 Inhibition ofLipolysis
Reduction of circulating NEFA concentrations by using lipolysis inhibitors such as the
agent acipimox have been shown to have favourable effects on insulin sensitivity in
healthy controls and in subjects both with impaired glucose tolerance and type 2 diabetes
(Fulcher, Catalano et al. 1992; Fulcher, Walker et al. 1993; Walker, Agius et al. 1993).
Acipimox therapy has also been shown to reverse the decline in insulin sensitivity seen
with exogenous growth hormone therapy in individuals with growth hormone deficiency
(Nielsen, Moller et al. 2001). However, to date there are no studies of adjunctive therapy
with acipimox in Type 1 Diabetes.
1.9. Aims of this Thesis
The work reported in this thesis aims to gain further insight and knowledge into the
growth hormone - 1GF-1 axis in young adults with Type 1 Diabetes. Detailed
physiological studies before and after specific growth hormone blockade will extend
knowledge and understanding of the physiological impact of growth hormone
hypersecretion on glucose and lipid metabolism in young people with Type 1 Diabetes
and may ultimately facilitate development of a viable adjunctive therapy which may
improve glycaemic control and afford protection against the risk of the complications of
diabetes.
Previous studies have demonstrated that administration of exogenous IGF-I at
physiological doses to young people with Type 1 Diabetes leads to suppression of
growth hormone secretion and enhancement of insulin sensitivity. However, concern
regarding the safety profile of IGF-I when administered at high doses led to its
withdrawal from development as a potential therapy in Type 1 Diabetes. More recently,
rhIGF-I complexed to rhIGFBP-3 has been developed as a means of prolonging the half-
life of IGF-I and reducing the risk of potentially dangerous side effects. The work
reported in this thesis should increase understanding of the pharmacokinetics of rhlGF-
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I/rhIGFBP-3 complex, particularly effects on plasma concentrations of IGFBP-3 and on
IGFBP-3 proteolysis.
Finally, growth hormone hypersecretion has been implicated in the pathogenesis of the
complications of diabetes, and may lead to glomerular hyperfiltration and
microalbuminuria. Detailed physiological evaluation of renal haemodynamics and
urinary albumin excretion rates following suppression of endogenous growth hormone
secretion by the exogenous administration of IGF-I complexed to its natural carrier
protein; IGFBP-3 will increase understanding of growth hormone's role in the
glomerular hyperfiltration and renal disease in type one diabetes.
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Chapter 2: SPECIFIC GROWTH HORMONE
RECEPTOR BLOCKADE IN Type 1 Diabetes
2.1. Introduction
This chapter will describe a physiological study undertaken using the specific growth
hormone antagonist; B2036-PEG (Pharmaceutical name Pegvisomant, Brand name
Somavert®, Pfizer, UK) in young adults with type one diabetes. The study was of
randomised crossover design, comparing the effects of 2 doses of B2036-PEG (5 and
lOmg) on insulin sensitivity and glucose and lipid metabolism, assessed at baseline and
following each of 2 treatment blocks.
2.2. Rationale
The preliminary data from animal and human studies suggest that B2036-PEG can
effectively block the actions of growth hormone, and is relatively free of side effects. By
blocking the adverse metabolic effects of growth honnone on carbohydrate and lipid
metabolism, despite reducing IGF-I concentrations, adjunctive therapy with B2036-PEG
may improve insulin sensitivity in Type 1 Diabetes.
2.3. Methods
2.3.1 Study Design
The study was an investigator blinded, randomised crossover study of two 3-week
treatment periods with either 5 or lOmg B2036-PEG administered once daily via
subcutaneous injection for 3 weeks, separated by a 3-week washout period. There was a
3-week run in period at the beginning and a 3-week run out at the end. The study
schedule is shown in Figure 5.
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Figure 5: Study Schedule
Schematic representation of the study schedule. Arrows denote the timing of overnight
euglycaemic clamp studies. Each subject received treatment with both doses (5 and lOmg)
of B2036-PEG in random order.
2.3.2 Subjects
8 young adult subjects with Type l Diabetes were recruited for the study from diabetes
clinics in Cambridge, Aylesbury and Northampton, (3M, median age 18.7 years; (range,
17.3 to 22.6); median body mass index 26.7 Kg/m2; (range 22.2 to 28.2); median HbAlc
9.4% (range, 8.0-10.5)). All were post pubertal, with Type 1 Diabetes of at least 2 years'
duration, and were C-peptide negative. All had normal renal, hepatic and thyroid
function and a normal full blood count. None had any evidence ofmicroalbuminuria or
retinopathy. All were treated with a combination of short and long acting insulins two to
four times per day (median insulin dose 0.9u/Kg/24hrs (range 0.5-1.1)). Details of
individual subjects are given in Table 3.
The study protocol was approved by the Cambridge, Aylesbury and Northampton Local
Research Ethics Committees. Written, informed consent was obtained from all subjects
prior to the study. All overnight studies were performed at Addenbrooke's Hospital,
Cambridge, UK in the Wellcome Trust Clinical Research Facility.
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Table 3. Subject Characteristics




1 1 0.48 bd 18.5 27.1 F 10.5
2" 2 1.08 bd 17.5 23.2 F 10.0
3 1 1.14 MIT 18.0 28.2 M 8.6
4 2 0.52 MIT 17.7 22.2 F 7.2
5 2 0.90 MIT 18.1 26.7 F 10.1
6 1 0.51 MIT 22.6 24.8 M 8.0
7 2 0.99 MIT 17.3 27.3 M 10.8
8 1 0.94 MIT 18.9 24.0 F 9.4
# 1: Treatment order 5mg/day B2036-PEG in first block and lOmg/day B2036-PEg in second
block 2 Treatment order lOmg/day Somavert in first block and 5mg/day Somavert in second
block
a Subject 2 was excluded from analysis due to failure to omit long acting insulin prior to one of
the study nights, thus invalidating any data.
2.3.3 Study Timetable
2.333 Run in Period
Baseline HbAlc, toxicology (full blood count, liver function tests and urea and
electrolytes), IGF-I and IGFBP-3 were measured at screening. During the run in period,
subjects were contacted weekly by phone and insulin dose was titrated according to
home blood glucose monitoring to achieve optimal glycaemic control. A baseline
overnight assessment of insulin sensitivity and glucose and lipid metabolism, followed
by hyperinsulinaemic clamp was performed at the end of this period (please see section
2.3.4 for details).
2.3.3.ii Treatment periods
During each treatment period, subjects were randomised to receive either 5 or lOmg of
B2036-PEG (S5 and S10 respectively) once daily via subcutaneous injection in addition
to their usual insulin regimen. The investigator was blinded as to the order in which each
subject received the doses until after the completion of the study. At the beginning of
each treatment block, subjects were advised to reduce their total daily insulin dose by
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20% in order to minimise the risk of hypoglycaemia. Thereafter, insulin requirements
were titrated according to home blood glucose monitoring following telephone liaison
with the investigator (please see Appendix 1 for details). Overnight assessments of
insulin sensitivity and glucose and lipid metabolism, followed by hyperinsulinaemic
clamp, identical to that performed at baseline, were performed on day 21 of each
treatment period (please see section 2.3.4 for details).
2.3.3.iii Wash out and Run Out Periods
During these periods, subjects received their usual insulin regimen and regular telephone
contact was maintained with the investigator with insulin dose being titrated according
to home blood glucose monitoring.
2.3.4 Overnight Variable Rate Insulin Infusion
For the 36 hours prior to admission for each overnight study, all intermediate and long
acting insulin was withdrawn. During this time, blood glucose was controlled with
multiple daily injections of soluble insulin, with the last injection being given between
noon and 1300h on the day of the study. Subjects were admitted to the clinical
investigation ward at 1700h and an intravenous cannula was sited in a vein in each arm;
one for purposes of sampling and one for intravenous infusion. Subjects chose a meal
from the ward menu (they received an identical meal on each of the 3 overnight visits)
which was given atl 800h and were subsequently fasted until noon the next day.
Between 1800 and 0800h, a variable rate insulin infusion was administered. Blood
glucose was determined every 15 minutes and the insulin infusion rate adjusted to
maintain blood glucose at 5mmol/l: no glucose was administered during this period. In
addition to glucose, samples were taken for growth hormone (15 minutely) and free
insulin (every 30 minutes). Samples for non esterified fatty acids (NEFA), IGFBP-1, and
ketones (AHA and BOHB) were taken every hour. During the overnight period and
hyperinsulinaemic clamp a sampling chart was used for reference which is reproduced in
Appendix 2.
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2.3.5 Hyperinsulinaemic Euglycaemic Clamp
Between 0800 and 1200h the following morning, a 2-step hyperinsulinaemic
euglycaemic clamp study, incorporating glucose and glycerol cold isotopes was
performed as follows. At 0500h primed infusions ([6,6 2H2] glucose, 170mg intravenous
bolus followed by continuous infusion, 1.7mg/min and 2H5 glycerol, 0.61mg/Kg bolus
followed by 0.15mg/kg/min continuous infusion) were commenced and continued for
the duration of the study. Between 0800h, and lOOOh, step 1 of the hyperinsulinaemic
clamp was performed (insulin bolus 3.5mU/Kg followed by insulin infusion
0.75mU/Kg/min). Between lOOOh and 1200h, step two (insulin bolus 7mU/Kg followed
by insulin infusion 1.5mU/Kg/min) of the hyperinsulinaemic clamp was performed.
During the hyperinsulinaemic clamp, blood glucose was determined every 5 minutes and
maintained at 5mmol/l using a variable rate 20% dextrose infusion. The 20% dextrose
was enriched with 700mg [6,6 2H2] glucose per 500ml bag to prevent marked decreases
in blood tracer enrichment and consequent calculation errors. Serum enrichment of [6,6
2H2] glucose and 2H5 glycerol were determined every 5 minutes during each of 3 steady
state period (baseline 0730 to 0800h, step one 0930 to lOOOh and step two 1130 to
1200h).
Throughout the study period (1800h to 1200h), blood samples were taken regularly for
determination of free insulin (30 minutes), IGFBP-1, NEFA and P-hydroxybutyrate (60
minutes). A sample was collected at 0800h for IGF-I and IGFBP-3 determination.
Subjects remained supine throughout the study period and had similar sleep patterns
during each night of observation.
2.3.6 Laboratory Analysis
Blood glucose concentrations were measured using 25pl whole blood samples on a
Y.S.I, model 2300 stat plus analyser (YSI Incorporated, Yellow Springs, Ohio 45387
USA). The intra-assay coefficient of variation (CV) at 4.1 mmol/L is 1.5%. The
equivalent inter-assay CV at this glucose concentration was 2.8%, and was 1.7% at 14.1
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mmol/L. Plasma insulin concentrations were measured by ELISA, using a commercial
kit (DSL, Tooting, London) according to the manufacturer's instructions. The sensitivity
of this assay was 0.26 mU/L. Intra-assay imprecision (CV) was 4.4% at 10.3 mU/L and
5.1% at 35.8 mU/L. Equivalent inter-assay imprecision was, 8.7% and 2.9%
respectively. Plasma (total) IGF-I concentrations were measured in ethanolic extracts by
ELISA, (DSL, Tooting, London, UK). The sensitivity of this assay was 0.03 ng/mL.
Intra-assay imprecision (CV) was 8.8% and 9.4% at 107 and 262ng/ml respectively.
Equivalent inter-assay imprecision (CV) was 6.1% and 8.0% at 107 and 262ng/ml
respectively, respectively. Plasma (total) IGFBP-1 levels were measured by ELISA,
(DSL, Tooting, London, UK). The sensitivity of this assay was 0.25 ng/mL. Intra-assay
imprecision (CV) was 6.1% at 7.0 ng/mL and 5.3% at 48.4 ng/mL. Equivalent inter-
assay imprecision was, 10.4% and 5.1% respectively. Plasma IGFBP-3 levels were
measured by ELISA, (DSL, Tooting, London). The sensitivity of this assay was
0.04ng/mL. Intra-assay imprecision (CV) was 4.9% and 2.8% at 5.2 and 34.7ng/ml
respectively. Equivalent inter-assay imprecision (CV) was 9.7% and 1.9% at 5.2 and
34.7ng/ml respectively.
Plasma glycerol concentration was measured by a direct enzymatic colorimetric method
(Randox Laboratories Ltd, County Antrim, UK), (inter assay CV 3.7%) and NEFA was
measured by an enzymatic colorimetric method (Wako chemicals, Neuss, Germany),
(inter assay CV 3.6%) using a Cobas Fara II autoanalyzer (Roche, Welwyn Garden City,
U.K.). 6-hydroxybutyric acid (BOHB) was measured using a standard enzymatic
technique (Sigma Diagnostics, 6-hydroxybutyric acid kit, Poole, Dorset, UK).
Glucose and glycerol enrichment were measured by gas chromatography mass
spectrometry (GC-MS) using a Hewlett Packard 5971A MSD (Agilent Technologies,
Berks, UK). Glucose enrichment was determined from deproteinised plasma using the
methoxime-trimethylsilyl ether derivative (Shojaee-Moradie, Jackson et al. 1996).
Glycerol was isolated from deproteinised plasma using ion exchange chromatography
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and glycerol enrichment was determined using the tris-trimethylsilyl derivative (Wolfe
1992; Elia, Kahn et al. 1993). GC-MS analysis used electron impact ionisation with
selected ion monitoring of the ions at mass/charge ratio (m/z) 319 and 321 for glucose
and 205 and 208 for glycerol.
2.3.7 Calculations
23.1.\ IGF-I/IGFBP-3 Molar Ratio
The molar ratio of total plasma IGF-I to IGFBP-3 was calculated according to the
molecular weights of IGF-I and IGFBP-3 according to the following formula, using a
molecular weight of 33 -kDa for IGFBP-3 and 7.5 -kDa for IGF-I.
Molar Ratio = 33 x [IGF-I (ng/ml)]
7.5 x [IGFBP-3 (ng/ml)]
2.3.7.ii Glucose Infusion Rate
Total body glucose utilisation (M value, mg/Kg/min) was determined during the final 30
minutes of both steps of the hyperinsulinaemic clamp. The mean rate of 20% dextrose
infusion was calculated during the final 30 minutes of each step of the
hyperinsulinaemic clamp (MnRate) and converted from ml/hour to mg/kg/min using the
formula:
M value (mg/kg/min)=MnRate/60 (ml/min)/ x 0.2 x 1000 (mg/ml) /weight (kg)
2.3.7.iii Insulin Clearance
Insulin Clearance (ml.kg/min) = Insulin Infusion Rate (mU/kg/min)
Mean plasma insulin concentration (mU/ml)
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2.3.7.iv Glucose and Glycerol Turnover
The enrichments of glucose and glycerol were expressed as the tracer/tracee ratio. The
rates of appearance and disposal of glucose and glycerol were calculated using both the
Steele and Mari models for the non-steady state modified for use with stable isotopes
(Steele 1959; De Bodo, Steele et al. 1963; Mari 1992). The effective volume of
distribution was assumed to be 143ml/kg for glucose and 230ml/kg for glycerol (Steele
1959; Mari 1992; Romijn, Coyle et al. 1993). The calculations were performed under the
supervision of Drs Fariba Shojaee-Moradie and Margot Umpleby (Department of
Diabetes and Metabolism, St. Thomas's Hospital, London, United Kingdom) using
Microsoft Excel.
2.3.8 Statistical Analysis
Where data were normally distributed they were analysed using parametric tests. Serum
insulin, IGFBP-1, IGFBP-3 and BOHB were not normally distributed and were log
transformed (base 10) to permit parametric testing. The square root ofNEFA values was
used for analysis. Glucose Ra and Rd and glycerol Ra values were log transformed (base
e) prior to analysis.
Repeated measures ANOVA was used to confirm the overnight steady state period of
euglycaemia (0300-0800h). During this period of time there was no variation in blood
glucose concentration with time; nor any difference in blood glucose concentrations
between the 3 different study nights. This defined period of euglycaemia was then used
to compare differences in insulin requirements, insulin concentrations and ketone body
concentrations between the three study nights.
Comparisons ofmeans of the 3 study nights were made using Students /-tests for paired
samples, with each treatment period being compared with baseline. Differences in
glucose and glycerol turnover were analysed using repeated measures ANOVA across
time, with each treatment night being compared against the baseline night. SPSS version
10 (SPSS, Chicago, IL, USA) was used for all statistical analysis, p values less than 0.05
- Page 50 -
(two tailed) were considered statistically significant. Data are expressed as mean ± SEM
unless otherwise stated.
2.4. Results
2.4.1 Randomisation and Carry Over Effect
4 subjects (2M) received 5mg B2036-PEG (S5) first and 3 (1M) lOmg B2036-PEG
(S10) first (Table 3). There was no carry-over effect observed; IGF-I levels were similar
to those at baseline after treatment block 1, prior to treatment block 2, regardless of the
order in which subjects received B2036-PEG; IGF-I concentration 223.5 ± 23.9 ng/ml






Figure 6: IGF-I Concentrations Throughout the Study
Total IGF-I concentrations throughout the study shown chronologically rather than by
dose. Error Bars represent 1 SEM.
2.4.2 Adverse Events
No serious adverse events were reported during the study. 2 subjects reported local
swelling at the injection site, which spontaneously resolved within 2 hours. There were
no episodes of severe hypoglycaemia reported by any subject during any part of the
study protocol.
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2.4.3 IGF-I and IGF Bindingproteins
Effects of treatment with B2036-PEG on concentrations of IGF-I and IGFBP-3 are
summarised in Table 4. Treatment with 5mg B2036-PEG tended to lower IGF-I
concentration but this did not reach significance (Figure 7, Table 4). Treatment with
lOmg B2036-PEG led to a 30% reduction (p=0.01) in IGF-I concentrations after 3
weeks of treatment (Figure 7, Table 4). IGFBP-3 tended to be lower following treatment
with B2036-PEG; (3.0 ± 1.2 mcg/ml at baseline vs 2.9 ± 0.3 following S5 and 2.7 ± 0.3
following S10), however this did not reach significance (Table 4). Similarly, the IGF-
I/IGFBP-3 molar ratio tended to be lower following treatment with B2036-PEG; (0.48 ±
0.05 at baseline vs 0.39 ± 0.05 following S5 vs 0.39± 0.08 following S10) but did not
reach statistical significance with either dose (p=0.09) (Table 4).
Table 4. Effects ofB2036-PEG on IGF-I and IGFBP-3
(*p<0.05 vs pre treatment)
Pre Treatment 5mg B2036- 10mgB2036-r
PEG PEG
IGF-I (ng/ml)
% Change in IGF-I
IGFBP-3 (pg/ml)
IGF-I/IGFBP-3 Molar Ratio
223.5 ± 23.9 183.8 ±38.1 154.6 ±28.1 *
0 -16.3 + 11.3 -36.2 ±7.3
3.01 ±0.1 2.94 ±0.3 2.69 ±0.3
0.48 ±0.05 0.39 ±0.05 0.39 ±0.08
I

















Pre Treatment 1 week on End of Treatment 1 week off 3 weeks off
Treatment Period (3 weeks) Treatment Treatment
Figure 7: Dose Effects on IGF-I Concentrations
Upper Panel (black squares) 5mg Lower Panel (black diamonds) 1 Omg. Error Bars
represent +/- 1 SEM * p=0.004 vs Pre Treatment ** p=0.01 vs Pre Treatment
2.4.4 HbAlc
HbA 1 c was measured regularly throughout the study in a central laboratory. By the end
of the run-in period, HbAlc levels (%) had fallen from 9.2 ± 0.5 to 8.8 ± 0.6 & (p=0.03)
Thereafter it remained relatively constant and drifted back up again towards the end of
the study (Figure 8).
B2036-PEG 5mg once daily No Treatment
B2036-PEG 10mg once daily No Treatment








% V V % \
Figure 8: HbAlc throughout the study
Mean HbAlc represented chronologically throughout the study period. Error bars
represent 1 SEM
2.4.4.i Overnight Steady State Euglycaemia
The overnight steady state period of euglycaemia (5mmol/l) was defined between 0300
and 0800h. During this time period, there was no difference across time, within or
between individuals, on each of the 3 study nights (Table 5). This period was established
using a repeated measures ANOVA model. Blood glucose concentrations on the 3 nights
are shown in Figure 9.
2.4.4.ii Overnight Insulin Requirements
During the steady state period (0300-0800h) of euglycaemia (5mmol/l), there was no
significant difference in blood glucose levels on the three study nights, but mean insulin
infusion rates (mU/Kg/min) were reduced following treatment with B2036-PEG (0.35 ±
0.03 at baseline vs 0.25 ± 0.01 {p=0.02) following S5 and 0.35 ± 0.03 at baseline vs 0.24
± 0.01 (/?=0.004) following S10 (Table 5, Figure 10).
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Steady State Period
Time
Figure 9: Overnight bloodglucose profiles
Mean blood glucose concentrations during the overnight insulin infusion for euglycaemia
on the 3 study nights at baseline (pink), following treatment with 5mg (blue) and lOmg
(green) B2036-PEG for 3 weeks. Steady state period of euglycaemia (0300 to 0800h)
denoted by the shaded box. Error bars represent 2 SEM.
Figure 10: Overnight Insulin Requirementsfor Euglycaemia
Overnight (0300-0800h) insulin requirements (mU/Kg/min) for euglycaemia (5mmol/l) at
baseline (white bar), following 5mg B2036-PEG (grey bar) and following 3 weeks lOmg
B2036-PEG (black bar). * p<0.05 **p<0.001
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2.4.4.iii Plasma insulin and IGFBP-1 concentrations
There were no differences in plasma free insulin levels during steady state euglycaemia
on the three study nights (Table 5) and although corresponding reductions in derived
insulin clearance were observed, they were not significant (Table 5). Plasma IGFBP-1
concentrations were increased following treatment with lOmg B2036-PEG (Table 5).
Table 5. Effects ofB2036-PEG on Overnight Glucose and Lipid Metabolism during Steady
State Euglycaemia (0300 to 0800h)




5mg B2036-PEG 1 Omg B2036-PEG
Glucose (mmol/1) 5.3 ±0.07 5.1 ±0.04
Insulin Requirement (mU/Kg/min) 0.34 ± 0.03 0.25 ± 0.01 *
Plasma Insulin (mU/1) 21.8 ±2.4 19.3 ±1.4
Insulin Clearance Rate (ml.kg/min) 14.1 ± 1.5 14.2 ± 1.1
NEFA (mmol/1) 0.51 ±0.04 0.52 ±0.04
B-Hydroxybutyrate (mmol/1) 0.31 ±0.04 0.25 ± 0.05
IGFBP-1 (ng/ml) 41.5 ±4.5 45.5 ± 7.5
5.5 ±0.09
0.24 ± 0.02 **
18.3 ± 1.6
12.7 ± 1.3
0.38 ± 0.04 *
0.15 ±0.02**
55.4 ±4.4 *
2.4.4.iv Non esterified fatty acids and B- hydroxybutyrate
Treatment with S10 led to a significant reduction in mean overnight NEFA
concentrations (Figure 11), (0.51 ± 0.04 mmol/1 before treatment vs 0.38 ± 0.04
following S10, p=0.03) but not during the hyperinsulinaemic clamp. Overnight mean
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130HB levels were also reduced following S10 (0.31 ± 0.04 mmol/1 before treatment vs
0.15 ± 0.02 following S10, p=0.001).
3:00 4:00 5:00 6:00 7:00 8:00
Figure 11: Effects ofB2036-PEG on overnight NEFA levels
Mean NEFA concentrations (mmol/1) during overnight (0300-0800h) steady state
euglycaemia (5mmol/l) at baseline (white squares, solid line) and following 3 weeks lOmg
B2036-PEG (black squares, broken line). Error bars represent 1 SEM.
2.4.5 Hyperinsulinaemic Euglycaemic Clamp
Data from the hyperinsulinaemic clamp are summarised in Table 6.
2.4.5.i Glucose and insulin concentrations
There was no difference between occasions in glucose or insulin concentrations during
either step of the hyperinsulinaemic clamp (Table 6).
2.4.5.ii Glucose infusion rate
Glucose infusion rate (mg/mg/min) did not change during either step of the
hyperinsulinaemic clamp following treatment with either dose of B2036-PEG (Table 6).
2.4.5.iii Endogenous hepatic glucose production
There was no change in endogenous hepatic glucose production (endoRa) at baseline
(0730-0800h) or during either step of the hyperinsulinaemic clamp following treatment
with B2036-PEG (Table 6).
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2.4.5.iv Peripheral glucose utilisation
There was no change in peripheral glucose utilisation (Rd) at baseline (0730-0800h) or
during either step of the hyperinsulinaemic clamp following treatment with B2036-PEG
(Table 6).
2.4.5.V Glycerol turnover
Treatment with S10 led to reductions in glycerol turnover across the whole study period,
but differences were not detected when each steady state was considered separately
(Figure 12). Treatment with S5 had no effect on glycerol turnover.
Time
Figure 12: Effects ofB2036-PEG on Glycerol Turnover
Basal glycerol Turnover (0730 to 0800h) and during the 2-step hyperinsulinaemic
euglycaemic clamp at baseline (open squares, solid line) and following treatment with S10
(black squares, dotted line).
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Table 6. Datafrom the Hyperinsulinaemic Clamp
Effects ofB2036-PEG on insulin sensitivity and lipid metabolism during the two-step
hyperinsulinaemic clamp study. Baseline values were determined 0730-0800h. Step one
(0.75mU/Kg/min) was performed from 0800-1000h and step 2 (1.5mU/Kg/min) from 1000-
1200h.
Following Following
Pre-Treatment 5mg B2036-PEG lOmg B2036-PEG
Glucose
Step One 4.9 ± 0.02 5.0 ±0.03 4.9 ± 0.03
(mmol/1)
Step Two 5.0 ± 0.06 5.0 ±0.06 4.9 ±0.04
Plasma Insulin
Step One 54.4 + 4.4 43.8 ±5.9 53.1 ±4.6
(mU/1)
Step Two 97.9 ± 5.3 98.4 ± 12.6 107.4 ±7.2
Glucose Infusion
Step One 3.0 + 0.4 2.6 ±0.3 3.1 ±0.5
Rate (mg/kg/min)
Step Two 7.9 + 0.6 7.0 ±0.9 7.8 ± 0.7
Baseline 9.6+1.6 9.8 ±0.8 8.5 ± 1.3
Glucose Ra
(pmol/Kg/min) Step One
4.1 ±0.9 3.6 ±0.6 2.6 ±0.9
Step Two 2.8 ± 1.8 2.1± 0.7 2.1 ±2.3
Baseline 9.2 + 1.3 10.2 ±0.7 9.7 ± 1.0
Glucose Rd
(pmol/Kg/min)
Step One 22.1 ± 2.8 18.9 ± 2.1 22.1 ±3.7
Step Two 50.1 ±4.6 42.1 ±5.1 46.1 ±6.8
Glycerol Baseline 5.0 ±0.9 3.6 ±0.4 4.2 ±0.5
Production Rate
(pmol/Kg/min) Step One 2.2 ±0.2 2.5 ±0.4 1.8 ±0.2
Step Two 1.1 ±0.3 2.4 ±0.5 1.4 ±0.2
NEFA (mmol/1) Step One 0.21 ±0.05 0.26 ± 0.04 0.16 ±0.02
Step Two 0.04 ±0.01 0.07 ± 0.03 0.02 ± 0.00
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2.5. Discussion
Growth hormone has been implicated in the increased overnight insulin requirements
seen in subjects with Type 1 Diabetes during puberty and in the pathogenesis of the
dawn phenomenon. These data support this hypothesis, as 3 weeks' treatment with both
5 and lOmg B2036-PEG led to significant reductions in overnight insulin requirements.
The extent to which these changes are mediated by suppression of growth hormone's
known effects on lipolysis and NEFA generation, or by direct effects on peripheral
glucose utilisation by muscle, or suppression of hepatic glucose production, remains
uncertain. Increased overnight rates of lipolysis in young adults with Type 1 Diabetes,
which are not corrected by a preceding period of euglycaemia has been reported, and
may be related to increased growth hormone secretion (Hagstrom-Toft, Bolinder et al.
1997). Studies using the nicotinic acid analogue acipimox, which inhibits lipolysis,
leading to reduced plasma NEFA levels, have demonstrated enhancement of insulin
sensitivity in young, non-obese adults with T2DM (Fulcher, Catalano et al. 1992;
Walker, Agius et al. 1993). A recent study has shown that withdrawal of growth
hormone treatment in growth hormone deficient adults results in a decrease in glycerol
and NEFA production rate, measured using stable isotopes, and an increase in insulin
sensitivity (Gibney, Healy et al. 2003). Use of acipimox to prevent the rise in NEFA
following growth hormone administration to growth hormone deficient subjects prevents
the subsequent decline in insulin sensitivity (Nielsen, Moller et al. 2001). The data
presented in this chapter data support a role of growth hormone in the regulation of
lipolysis overnight, as blockade with the higher dose of B2036-PEG resulted in reduced
NEFA and BOHB levels overnight and glycerol turnover rate during the clamp study.
However, reduction in overnight insulin requirements for euglycaemia were also
observed with the 5mg dose of B2036-PEG, yet NEFA levels, BOHB levels and glycerol
turnover rates were not different from the baseline study. Given that the lower dose of
B2036-PEG did not alter overnight NEFA or BOHB levels, or glycerol production rate,
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it is possible that there is some direct effect of growth hormone blockade on hepatic
insulin sensitivity.
The observed reductions in insulin requirement for euglycaemia were accompanied by a
reduction in plasma insulin levels that was non-significant and was not accompanied by
a discernible change in insulin clearance. It has previously been reported in adolescents
with Type 1 Diabetes that overnight growth hormone concentrations are inversely
related to overnight insulin requirements and directly related to insulin clearance
(Acerini, Cheetham et al. 2000). Growth hormone blockade is unlikely to affect
overnight insulin requirements through changes in IGF-I as there was no effect on IGF-1
concentrations with the lower dose (although this may reflect the small sample size).
Contrastingly, with S10, there was a reduction in IGF-I concentrations. Reductions in
IGF-I were accompanied by non-significant changes in IGFBP-3 and a reduction in the
IGF-I/IGFBP-3 molar ratio, suggesting a possible reduction in free, or bio available
IGF-I. Increases, rather than decreases in IGF-I have previously been shown to reduce
overnight insulin requirements, both directly (Crowne, Samra et al. 1998), and
secondary to reductions in growth hormone secretion (Acerini, Harris et al. 1998). These
data suggest that growth hormone blockade has effects on overnight insulin sensitivity
that are independent of IGF-I, with an indirect effect on lipolysis seeming the most
likely explanation, given the observed effects on lipolysis.
The reduction in IGF-I concentrations following growth hormone blockade may
contribute to the failure to observe any changes in insulin sensitivity during the
hyperinsulinaemic clamp the following morning, as IGF-I has been directly implicated
both in hepatic and peripheral insulin sensitivity during a hyperinsulinaemic clamp.
Direct effects of suppression of IGF-I concentrations on insulin sensitivity may therefore
have ameliorated any beneficial effects of the indirectly beneficial effects of growth
hormone blockade. Growth hormone blockade with B2036-PEG is prolonged and has
been reported not to cause rebound stimulation of GH release via the hypothalamic-
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pituitary axis (Thorner, Strasburger et al. 1999). As such, pharmacological blockade of
the growth hormone receptor should have been maintained throughout the clamp period
and NEFA were rapidly suppressed by insulin during step 1 of the hyperinsulinaemic
clamp on all occasions; yet greater suppression of glycerol turnover following SI 0 was
evident throughout the hyperinsulinaemic clamp. However, despite the greater
suppression of glycerol production rate, insulin sensitivity in respect of either hepatic
glucose production, or peripheral glucose utilisation remained unchanged.
This work would have been strengthened by the inclusion of placebo control data. In
addition, there is always the possibility that changes in insulin action overnight might be
secondary to a non-specific improvement in diabetes control. However this would not
explain the lack of effect on insulin sensitivity during the clamp the following morning.
The sample size of 7 subjects should have provided 80% power with 5% significance to
detect a 30% change in endogenous hepatic glucose production during step one of the
hyperinsulinaemic clamp. A larger sample size may have detected effects on insulin
sensitivity of lesser magnitude.
Persisting IGF-I deficiency, particularly following S10 may explain the absence of
change in insulin stimulated glucose disposal during the morning hyperinsulinaemic
clamp. Recent studies have demonstrated that variation in free IGF-I levels following
exogenous administration of rhIGF-I may be an important determinant of insulin
sensitivity (Frystyk, Hussain et al. 1997). Unfortunately, in this study, there was
insufficient blood available to allow determination of free IGF-I. Despite reports of
decreased type 1 IGF receptor expression in the liver (Caro, Poulos et al. 1988), rhIGF-I
administration leads to reductions in hepatic glucose production rate and increased
peripheral glucose uptake (Acerini, Harris et al. 1998; Carroll, Christ et al. 2000; Cusi
and DeFronzo 2000). The effects of IGF-I on adipose tissue in humans remains unclear,
as human adipocytes do not express the type 1 IGF receptor (Frick, Oscarsson et al.
2000). In vitro studies have demonstrated that incubation of adipocytes with IGF-I
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stimulates glucose uptake and lipogenesis, but these insulin-like effects are likely to be
mediated via the insulin receptor (Siddals, Westwood et al. 2002). Thus reduced 1GF-I
levels following S10 could counteract any effects of growth hormone blockade and
suppression of lipolysis on insulin sensitivity through direct effects at the liver and via
the type 1 IGF receptor in other tissues such as muscle.
Alternatively, failure to observe an increase in insulin sensitivity during the
hyperinsulinaemic clamp may reflect the method used to quantify insulin sensitivity
rather than a true absence of change. Treatment with S10 led to a suppression of
lipolysis overnight, with reductions in concentrations of free fatty acids. NEFAs are
known to cause insulin resistance by the competitive inhibition of glucose transport into
the cell by GLUT4 (Shulman 2000). The overnight insulin infusion for euglycaemia, is,
by its very nature, physiological, with SI0 treatment leading to an increase in insulin
sensitivity. However, even during the first step of the hyperinsulinaemic clamp, doses of
insulin are used which lead to plasma insulin concentrations which greatly exceed
physiological levels; around 50mU/l (approximately 300pmol/l). If specific growth
hormone blockade affects insulin sensitivity predominantly by its effect on lipolysis,
which is exquisitely sensitive to insulin, as soon as the hyperinsulinaemic clamp
protocol is commenced, any effect mediated via lipolysis will immediately by
ameliorated by the resultant supra-physiological concentrations of insulin. The
hyperinsulinaemic clamp technique, although the current 'gold standard' methodology
for the physiological assessment and quantification of insulin sensitivity, was developed
for the study of individuals with insulin resistance and impaired glucose tolerance, in
whom plasma concentrations of insulin are chronically elevated and it may not be the
ideal tool for the study of individuals with type one diabetes.
2.6. Conclusion
These data support the importance of overnight growth hormone, lipolysis and NEFA
modulation in the pathogenesis of the dawn phenomenon in Type 1 Diabetes, although
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they suggest that IGF-I concentrations may be the more relevant determinant of insulin
sensitivity the next morning as determined by a hyperinsulinaemic euglycaemic clamp.
The therapeutic potential of growth hormone inhibition with B2036-PEG, which is safe
and well tolerated, may therefore depend on the relative degree of reduction in IGF-I
concentrations. In this respect, there were observed reductions in overnight insulin
requirement with S5, without compromising IGF-I concentrations, although, with less
effect on lipolysis than observed with S10: data suggesting that doses of B2036-PEG
could be titrated in order to achieve optimal glycaemic control.
It would be extremely interesting to expand the overnight study of glucose turnover to
utilise cold isotope methodology throughout the overnight period of euglycaemia, before
and after treatment with a growth hormone antagonist in order to further evaluate basal
glucose turnover with physiological concentrations of insulin.
This study investigated the effects of specific growth hormone blockade on overnight
insulin sensitivity and lipolysis in a small group of young adults with type one diabetes.
The adjunctive therapy was well tolerated for a 3-week period with no serious side
effects and led to reductions in overnight insulin sensitivity, which appear to be
secondary to an effect on lipolysis. Large-scale clinical trials of at least 6 months of
therapy would be needed in order to ascertain clinically relevant effects on HbAlc as
well as evidence of safety and tolerability. However, specific growth hormone blockade
in this vulnerable subgroup of patients may be of benefit in order to optimise glycaemic
control during adolescence, thereby minimising the risk of the development of
complications later in life. Further short-term physiological studies looking at the effects
of specific growth hormone blockade on glomerular filtration rate and urinary albumin
excretion rates would be of interest.
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Chapter 3: THE EFFECTS OF rhIGF-I/rhIGFBP-3
COMPLEX ON RENAL PHYSIOLOGY IN Type 1
Diabetes
3.1. Introduction
This chapter describes a study undertaken to evaluate a potential role for manipulation of
the growth hormone - IGF-I axis in the risk of nephropathy development in young
people with Type 1 Diabetes. Recent data from the Oxford Regional Prospective Study
(ORPS) comparing microalbuminuria (MA) positive cases with MA negative controls
matched for age, sex, puberty stage and duration of diabetes suggest that cases have
lower total IGF-I concentrations, increased overnight growth hormone secretion and also
increased glomerular filtration rate (GFR) 5 years from diagnosis (prior to the
development ofMA) than controls (Amin, Turner et al. 2005; Amin, Williams et al.
2005). Increased secretion of growth hormone secondary to low circulating levels of
IGF-I may stimulate increased paracrine production of IGF-1 locally within the kidney
and promote microangiopathic changes (Segev, Landau et al. 1997).
There is compelling evidence from rodent models of diabetes that nephropathy
correlates directly with IGF-I expression within the kidney (Flyvbjerg 2000). An
experimental model of Type 1 Diabetes in mice has abnormalities of the growth
hormone - IGF-I axis similar to those seen in humans (Landau, Segev et al. 2000) and
administration of specific growth hormone antagonists (GHAs) to mice with
nephropathy leads to a reduction in renal expression of IGF-I, renal size, GFR, effective
renal plasma flow (ERPF) and urinary albumin excretion (Flyvbjerg, Bennett et al. 1999;
van Neck, Dits et al. 2000). Suppression of growth hormone secretion, or inhibition of
its actions, may be a possible therapeutic adjunct in those at risk of nephropathy.
The study described in this chapter examined the effects of restoration of IGF-I
concentrations using rhIGF-I/rhIGFBP-3 complex (Somatokine, SK) on overnight
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growth hormone secretion and insulin requirements, GFR, ERPF and urinary excretion
of albumin, retinol binding protein and growth hormone dependent peptides (IGF-I and
1GFBP-3) in normalbuminuric young adults with Type 1 Diabetes.
3.2. Methods
3.2.1 Study Design
The study was of randomised, double blinded, placebo-controlled crossover design.
Each subject received two, 7-day treatment blocks of rhIGF-I/rhIFBP-3 complex
(0.4mg/kg once daily via subcutaneous injection, equivalent to IGF-I 80mcg/kg/day) and
placebo in random order. There was a 2-week run in period and the treatment blocks
were separated by a 2-week washout period. Ethical approval was obtained from the
Cambridge Local Regional Ethics Committee and all studies were performed in the
Wellcome Trust Clinical Research Facility (WTCRF) at Addenbrooke's Hospital.
Written, informed, consent was obtained from all subjects, prior to commencement of
the study protocol.
3.2.2 Subjects
Seven subjects were recruited from the young adult diabetes clinic at Addenbrooke's
Hospital, Cambridge. Details of individual subjects are given in Table 7. Three were
male and median (Range) age was 21 (19-24) years with median (Range) HbAlc 8.9
(7.9-11.7) %. All were post pubertal, with Type 1 Diabetes of at least 2 years' duration,
and C-peptide negative. All had normal renal, hepatic and thyroid function and a normal
full blood count. None had any evidence of microalbuminuria or retinopathy. All were
treated with a combination of short and long acting insulins two to four times per day
(median insulin dose 0.9u/Kg/24hrs (range 0.5-1.1)). Seven subjects completed the study
protocol, but 1 subject (subject 7) was omitted from the analyses as she neglected to
omit her long acting insulin preparation prior to the second study night. One subject
(subject 3, female) withdrew from the study following screening. The study timetable
and investigations are shown in Figure 13.
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Table 7. Subject Characteristics at Recruitment




1 1 1.28 MIT 18.7 27.1 M 8.9
2 2 0.66 MIT 23.8 23.2 M 7.1
4 2 0.86 MIT 22.1 28.2 F 11.7
5 1 0.65 MIT 23.3 22.2 F 8.1
6 2 0.91 MIT 19.5 26.7 F 9.8
T 1 0.84 MIT 20.2 24.8 M 9.5
8 1 0.82 MIT 20.6 27.3 F 8.5
# 1: Treatment order Placebo followed by rhrhIGF-I/rhIGFBP-3 complex. 2 rhrhIGF-I/rhIGFBP-
3 complex followed by Placebo. MIT: multiple injection therapy.


























Figure 13: Study Schedule
Timetable of treatments and investigations. The overnight study performed at the end of
each treatment block comprises an overnight variable rate insulin infusion to achieve
euglycaemia (5mmol/l). SK: Somatokine rhIGF-I/rhlGFBP-3 complex.
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3.2.2.i Run in Period
The study commenced with a 2-week run in period. During this time, subjects were
encouraged to perform home glucose monitoring at least 3 times daily and insulin dose
was optimised.
3.2.2.ii Treatment Blocks
Each subject received 7 days treatment with placebo and rhIGF-I/rhIGFBP-3 complex
(Somatokine, SK) (0.4mg/kg once daily via subcutaneous injection) in random order,
separated by a 2-week washout period (Figure 13). Both subjects and investigator were
blinded as to treatment. For the purposes of safety a member of the diabetes team (Dr
Kevin Yuen) who was not otherwise involved with the study liased with subjects during
each treatment block regarding adjustment of insulin dose whilst receiving rhlGF-
I/rhIGFBP-3 complex in order to minimise risk of hypoglycaemia. Subjects were
advised to reduce their total insulin dose by 30% at the beginning of each treatment
block, regardless of treatment. For the remainder of the seven days, insulin dose was
titrated according to home blood glucose monitoring targets as outlined in Appendix 1.
Subjects were advised to administer the injection at the same time (1800h) each day, into
the left thigh. Subjects were issued with 7 days' supply of rhIGF-I/rhIGFBP-3 complex
or placebo which was stored frozen at -20 °C and removed 60 minutes prior to injection.
Vials were then left at room temperature to allow the contents to defrost and come up to
room temperature prior to injection.
3.2.3 24 hour Urine Collections
Subjects were asked to perform a total of four 24-hour urine collections throughout the
study; one at the beginning and one at the end of each treatment block. Subjects were
instructed to void their bladder on waking on the morning of the collection and
subsequently to collect all urine into a sterile, untreated container. On waking the
following morning, subjects were asked to completely empty their bladder, completing
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the 24-hour collection. Volume was then determined and aliquots of urine centrifuged at
3000rpm for 5min to precipitate debris. Aliquots were stored at -80°C until analysed.
3.2.4 Overnight Variable Rate Insulin Infusion
On the final day of each treatment block, subjects were admitted to the WTCRF for an
overnight study. All long and medium acting insulin was withdrawn for 24 hrs prior to
the overnight study. Subjects were admitted to the ward at 1730h and a cannula was
sited in each antecubital fossa; one for the purposes of sampling and one for the
purposes of infusion. A meal was given at 1800h (subjects were allowed to choose from
a selection of sandwiches, baked potatoes etc and each subject received identical meals
on both occasions).
Between 1800h and 0800h a variable rate insulin infusion for euglycaemia (5mmol/l)
was performed with determination of blood glucose every 15 minutes. Samples were
taken into lithium heparin tubes for determination of plasma growth hormone every 15
minutes and plasma IGF-I, IGFBP-1, IGFBP-3 and insulin concentrations every 60
minutes.
3.2.5 Estimation ofGFR andERPF
Following the overnight period of euglycaemia, subjects underwent the following
protocol to attempt estimation ofGFR and ERPF using standard clearances of
iothalmate and para-aminohippuric acid (PAH) respectively (Bell, Bombardt et al.
1994).
At 0700h infusions of iothalamate (bolus 20mg/kg followed by infusion rate 600mg/hr =
16pmol/min) and PAH (bolus 5mg/kg followed by infusion 750mg/hr) were
commenced. At 0600h, subjects were asked to orally ingest approximately 1000ml of
water in order to establish diuresis of the order of 10-25ml/min. If subjects were unable
to comply with this, a similar volume of 0.9% saline was administered intravenously
between 0700 and 0800h. After the initial hydration, subjects were asked to ingest
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sufficient water orally in order to keep pace with urinary losses and thus maintain the
diuresis.
After a 60 minute equilibration period, subjects were asked to empty their bladder
completely and baseline plasma samples were taken into lithium heparin for
determination of iothalamate and PAH. Subsequently plasma samples were taken every
10 minutes for determination of iothalamate and PAH and 3 accurately timed urine
samples were collected and volume determined by the use of electronic weighing scales
for determination of iothalamate and PAH concentration.
For valid use of standard clearance methodology adequate diuresis must be established
so that residual bladder volume is of minimal significance. Diuresis was considered
adequate if the calculated urinary excretion rate of iothalamate in an individual was
within 20% either side of expected (16pmol/min, the infusion rate). Where this was not
achieved, GFR was calculated from the continuous infusion clearance of iothalamate,
from the mean of plasma iothalamate concentrations at 30, 60 and 90 minutes (see
results section for further details). There is no alternative to standard clearance
methodology for determination of ERPF.
Iothalamate Clearance = Infusion Rate/ Plasma Concentration
GFR was subsequently corrected for body surface area and expressed / 1.73m2
3.2.6 Laboratory Methods
3.2.6.i Quantitative assay techniques: plasma
Blood glucose concentrations were measured using 25pi whole blood samples on a
Y.S.I, model 2300 stat plus analyser (YSI Incorporated, Yellow Springs, Ohio 45387
USA). The intra-assay imprecision (coefficient of variation, CV) at 4.1 mmol/L was
1.5%. The equivalent inter-assay CV at this glucose concentration was 2.8%, and was
1.7% at 14.1mmol/L.
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Plasma insulin concentrations were measured by ELISA, using a commercial kit (DSL-
UK Ltd, Upper Heyford, Oxon, UK) according to the manufacturer's instructions. The
sensitivity of this assay was 0.26 mU/L. Intra-assay CV was 4.4% at 10.3 mU/L and
5.1% at 35.8 mU/L. Equivalent inter-assay CV was, 8.7% and 2.9% respectively.
Plasma (total) IGF-I concentrations were measured in ethanolic extracts by ELISA,
(DSL-UK Ltd). The sensitivity of this assay was 0.03 ng/mL. Intra-assay CV was 8.8%
and 9.4% at 107 and 262ng/ml respectively. Equivalent inter-assay CV was 6.1% and
8.0% at 107 and 262ng/ml respectively, respectively.
Plasma (total) IGFBP-1 levels were measured by ELISA, (DSL-UK Ltd). The sensitivity
of this assay was 0.25 ng/mL. Intra-assay CV was 6.1% at 7.0 ng/mL and 5.3% at 48.4
ng/mL. Equivalent inter-assay CV was 10.4% and 5.1%, respectively.
Plasma IGFBP-3 levels were measured by ELISA, (DSL-UK Ltd). The sensitivity of
this assay was 0.04ng/mL. Intra-assay CV was 4.9% and 2.8% at 5.2 and 34.7ng/ml
respectively. Equivalent inter-assay CV was 9.7% and 1.9% at 5.2 and 34.7ng/ml
respectively.
Plasma creatinine and iothalamate were measured by stable isotope dilution electrospray
mass spectrometry-mass spectrometry. The creatinine assay has been reported
previously (Lamb, Wood et al. 2005). Standards, samples, and controls (5pl) were
diluted with 250pl of an aqueous internal standard mix (60pl lOmM iothalamate-d3 and
20pl lOmM creatinine-d3 per 100ml) directly into a 96 deep well (2ml) polypropylene
plate (Semat International Ltd, St Albans, UK) using a Hamilton Micro Lab M
(Hamilton, Carnforth, UK). Acetonitrile with 0.05% formic acid (250pl) was added to
each well and the plate covered with a sealing mat, mixed, centrifuged, and loaded onto
an CTC Analytics HTS PAL refrigerated autosampler (Presearch Ltd, Hitchin, UK) for
MSMS analysis. Samples (2pl) were automatically introduced into a continuous solvent
stream of acetonitrile:water (1:1) containing 0.025% formic acid flowing at 250pl/min
(Agilent 1100 series). Chromatography, to minimise matrix ion suppression effects, was
- Page 71 -
performed on a Symmetry C8, 3.5pm 2.1x50mm column with guard (Waters
Corporation, Watford, UK). MSMS was performed on a SCIEX API 4000 (Applied
Biosystems, Warrington, UK) triple quadrupole MSMS with an electrospray source in
positive ion multiple reaction monitoring (MRM) mode at 5250V and 250°C. The
interface heater was on and all other settings were optimized for the MRM transitions
m/z 114.2/44.2 for creatinine, m/z 117.2/47.2 for creatinine-d3, m/z 614.7/360.9 for
iothalamate, and m/z 617.7/363.9 for iothalamate-d3. Dwell time 150ms for each
transition. Inject to inject time 3min. The inter-assay CVs for creatinine at 65pmol/l and
iothalamate at 100pmol/l were 4.6% and 3.9%, respectively.
3.2.6.ii Quantitative assay techniques: urine
Urinary concentrations of IGF-I and IGFBP-3 were measured using commercially
available EUISA kits (DSL, Tooting, London, UK). Prior to analysis urine was
concentrated 10 fold (Centricon). For both peptides, the standard method was adapted to
incorporate incubation of samples with the primary antibody for 18 hours at 4°C.
Urine albumin and retinol binding protein were measured as previously described
(Tomlinson, Dalton et al. 1990; Schultz, Dalton et al. 2000), except that urine dilutions
and plating out were performed using a Hamilton Micro Lab Duo with a Micro Lab 500
(Hamilton, Carnforth, UK). Urine creatinine was measured by MSMS as above. lOpl of
urine was automatically diluted 1:100 with deionised water (Hamilton Micro Lab Duo
with a Micro Lab 500) and then further diluted 1:100 with creatinine-d3 internal standard
(20pl lOmM creatinine-d3 per 200ml deionised water) directly into a 96 deep well
polypropylene plate for MSMS analysis.
3.2.7 Randomisation
Randomisation was carried out by a third party who was not otherwise involved with the
study or any of the participants. Subjects were randomised using a random number
generator, and were stratified for gender in order to achieve equal proportions of both
sexes in each treatment arm. Allocation of treatment arms was concealed from members
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of the research team and study participants prior to randomisation. Treatment allocation
was held in a password protected computer file and was revealed only once the study
had been completed.
3.2.8 Statistical Analysis
Where data were normally distributed they were analysed using parametric tests. Serum
insulin, IGFBP-land IGFBP-3 were not normally distributed and were log transformed
(base 10) to allow parametric testing. All urinary data were log (10) transformed to
allow parametric testing. For albumin excretion rate, urinary retinal binding protein,
IGF-I and IGFBP-3, the change across each treatment block was calculated and then
paired Students /-tests used to analyse differences in change within individuals.
A repeated measures ANOVA model incorporating subject ID and treatment as fixed
factors was used to identify the overnight steady state period of euglycaemia (0200-
0700h). During this time there was no difference in blood glucose across time either
within or between individual subjects, or between placebo and rhIGF-I/rhIGFBP-3
complex.
Comparisons between means of variables collected during the 2 study nights were made
using Students /-tests for paired samples, with rhIGF-I/rhIGFBP-3 complex being
compared against placebo in each individual.
SPSS version 10 (SPSS, Chicago, IL) was used for all statistical analysis, p values less
than 0.05 (two tailed) were considered statistically significant.
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3.3. Results
Data are presented as mean (SD) or median (IQR) unless otherwise stated.
3.3.1 Randomisation
4 subjects were randomised to receive placebo first and rhIGF-I/rhIGFBP-3 complex
second and the remaining 3 received rhIGF-I/rhlGFBP-3 complex in their first treatment
block and placebo in the second.
3.3.2 Adverse Events
No serious adverse events occurred during the study. One subject reported mild bruising
at the injection site while taking rhIGF-I/rhIGFBP-3 complex and three subjects
complained ofmild discomfort when injecting rhIGF-I/rhIGFBP-3 complex. Great care
was taken to avoid hypoglycaemia, by reduction of insulin dose by around 30% while
taking the active compound. There were no episodes of severe hypoglycaemia (defined
as needing assistance from another individual) during the study, either in the rhlGF-
I/rhIGFBP-3 complex or the placebo arm.
3.3.3 Overnight Steady State Period ofEuglycaemia
The overnight steady state period of euglycaemia was defined as between 0200 and
0700h. During this time, euglycaemia was maintained at 5mmol/l on both nights; with
no significant difference in blood glucose across time on individual nights, or between
nights, either within or between individuals (Figure 14).
Compared to placebo, subjects required less insulin overnight to maintain euglycaemia
following seven days treatment with rhIGF-I/rhIGFBP-3 complex; 0.14 (0.1) vs 0.20
(0.2) mU/kg/min (p<0.04) (Figure 15).
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Figure 14: Overnight Period ofEuglycaemia
Mean glucose concentrations (mmol/1) during steady state euglycaemia (5mmol/l)
following placebo (blue) and rhIGF-I/rhIGFBP-3 complex (Somatokine) (pink). Error
bars denote 2 SEM.
3.3.4 Growth Hormone Secretion
Following rhIGF-I/rhIGFBP-3 complex treatment, mean overnight growth hormone
concentrations were lower following rhIGF-I/rhIGFBP-3 complex than following
placebo; 2.6 (0.5) mU/1 vs. 4.8 (0.5) (p<0.04).
e .2
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Figure 15: Overnight Insulin Requirements
Median (IQR) overnight (0200-0700h) insulin requirements for euglycaemia following
placebo (blue) and rhIGF-I/rhIGFBP-3 complex (Somatokine) 0.4mg/kg/24hrs (pink).
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3.3.5 IGF-1 Concentrations
The mean overnight plasma concentration of IGF-I was significantly greater following





Figure 16: IGF-I concentrations
Median (IQR) overnight (0200 to 0700h) concentrations of IGF-1 following seven days
treatment with placebo (blue) and rhIGF-I/rhIGFBP-3 complex (Somatokine)
0.4mg/kg/24hrs (pink). p<0.001
3.3.6 Concentrations ofIGFBP-3
The mean overnight plasma concentration of IGFBP-3 was greater following rhlGF-
I/rhIGFBP-3 complex treatment than following placebo; 4.5 (0.8) vs 4.0 (1.0) mcg/ml,
(p<0.04) (Figure 17).
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Figure 17: IGFBP-3 Concentrations
Median (IQR) overnight (0200 to 0700h) concentrations of IGFBP-3 following seven days
treatment with placebo (blue) and rhIGF-I/rhIGFBP-3 complex (Somatokine)
0.4mg/kg/24hrs (pink).
3.3.7 Plasma Creatinine Concentrations
Plasma creatinine concentration was lower following 7 days rhIGF-I/rhIGFBP-3
complex treatment than following placebo; 56.2 (12.8) vs 63.5 (15.0), (p<0.02).
3.3.8 Renal Physiology
In order to establish the validity of the standard clearance data for iothalamate and PAH,
the excretion rate of iothalamate over the total time of urine collection was determined
for each subject on each occasion. The expected excretion rate was 16p.mol/min
(equivalent to the infusion rate). Data were accepted if the calculated excretion rate fell
within 20% either side of this, i.e. between 12.8 and 19.2 pmol/min on both occasions.
Excretion rates of iothalamate for individual subjects on each of the 2 occasions are
shown in table 8. This was achieved in only 4 of the 7 subjects on both occasions, which
almost certainly reflects error due to residual bladder volume due to an insufficient urine
flow rate. This could explain both high and low excretion rates of iothalamate.
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Due to the inadequate nature of the data from the standard clearance calculations, these
were not included in analysis, and the steady state continuous infusion clearance of
iothalamate was used to determine GFR as an alternative. Unfortunately there is no
surrogate method for determination of ERPF and for this reason, no ERPF data are
presented.
Iothalamate Excretion Rate (pmol/min) Between 12.8 & 19.2
Subject Study 1 Study 2 on both occasions?
1 17.4 13.4 Yes
2 14.0 9.9 No
4 16.4 14.5 Yes
5 13.4 15.1 Yes
6 40.6 13.9 No
7 12.1 13.5 No
8 18.9 14.5 Yes
Table 8. Individual Excretion Rates oflothalamic Acid
Excretion rates of iothalamic acid in individual subjects on each occasion. The expected
excretion rate is 16pmol/min and data were acceptable only if the actual excretion rate fell
within 20% of this value (i.e. between 12.8 and 19.2 pmol/min) on both occasions
3.3.8.i Glomerular Filtration Rate
There was no difference in glomerular filtration rate following treatment with rhlGF-
I/rhIGFBP-3 complex when compared with placebo; 151.8 (17.6) vs 146.9 (22.2)
ml/min/1,73m2. Overall, 4 subjects had an increase in GFR, and 2 a reduction (Figure
18).
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Figure 18: Individual Glomerular Filtration Rates
Glomerular Filtration Rate in individual subjects following 7 day's treatment with placebo
and rhIGF-I/rhIGFBP-3 complex (Somatokine) 0.4mg/kg/24hrs.
There was no difference in AER before and after treatment with either placebo or rhlGF-
I/rhIGFBP-3 complex. There was no difference in the change in AER during treatment
with placebo or rhIGF-I/rhIGFBP-3 complex (Figure 19). Individual subjects' urinary
albumin excretion rates during the study are shown in Table 9.
3.3.10 Urinary Retinol Binding Protein
There was no difference between urinary concentrations of retinol binding protein
following treatment with rhIGF-I/rhIGFBP-3 complex or placebo; 15.3 (3.7) vs 16.3
(7.0) pg/mmol creatinine. There was no difference in the change in urinary
concentrations of retinol binding protein RBP between rhIGF-I/rhIGFBP-3 complex and
placebo; +2.6 (5.7) following placebo and +4.9 (4.9) pg/mmol creatinine following
rhIGF-I/rhIGFBP-3 complex.
3.3.9 Urinary Albumin Excretion Rate
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Placebo rhIGF-I/rhIGFBP-3 complex
Subject Pre Post Change Pre Post Change
1 10.3 9.9 -0.4 7.9 10.4 2.5
2 5.8 28.5 22.7 11.4 13.7 2.3
3 8.9 7.6 -1.3 5.5 11.0 5.5
4 11.1 9.0 -2.0 5.3 8.5 3.1
5 18.8 13.1 -5.7 11.2 12.1 0.9
6 4.3 8.3 4.0 15.5 8.1 -7.4
7 28.2 34.1 5.9 32.3 39.5 7.2
Mean 12.5 15.8 3.3 12.7 14.8 2.0
SD 8.4 10.8 9.4 9.3 11.1 4.7
Table 9. Albumin Excretion Rates
Albumin excretion rate (mg/24hr) before and after seven days' treatment with placebo and
rhIGF-I/rhIGFBP-3 complex 0.4mg/kg/day.
3.3.11 Urinary Excretion ofIGF-I and IGFBP-3
There was no difference between urinary excretion of IGF-I before and after treatment
with either placebo or rhIGF-I/rhIGFBP-3 complex (Table 10). Contrastingly, urinary
concentration of IGFBP-3 was increased following treatment with rhIGF-I/rhIGFBP-3
complex but not following placebo (Table 10, Figure 20).
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Figure 19: Urinary Albumin Excretion Rates
Effects of rhIGF-I/rhIGFBP-3 complex Treatment on Urinary Albumin Excretion Rate. A)
AER before and after placebo (blue) and rhIGF-I/rhIGFBP-3 complex 0.4mg/kg/24hrs
(pink) B) Change in AER over one week's treatment with placebo (blue) and rhlGF-
I/rhIGFBP-3 complex 0.4mg/kg/24hrs (pink).
Placebo rhIGF-I/rhIGFBP-3 Complex
Pre Post Pre Post
26.2 ± 8.5 33.1 ± 12.4 38.9 ± 15.9 38.4 ±14.7






Table 10. Effects ofrhIGF-I/rhIGFBP-3 complex on Urinary Excretion ofIGF-I and
IGFBP-3
Urinary concentrations of IGF-I and IGFBP-3 before and after treatment with placebo and
rhIGF-I/rhIGFBP-3 complex 0.4mg/kg/day for seven days. * p<0.005 compared with pre
treatment.
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Figure 20: Urinary Excretion ofIGFBP-3
Effects of rhIGF-I/rhIGFBP-3 complex (Somatokine) Treatment on urinary excretion of
IGFBP-3 as detected by EFISA, adjusted for urinary creatinine concentration. Error Bars
represent 95 % confidence intervals.
3.4. Discussion
Previously reported studies of 48-hours treatment with rhIGF-I/rhIGFBP-3 complex
have reported increases in insulin sensitivity comparable to those seen following
administration of rhIGF-I alone (Cheetham, Clayton et al. 1994; Acerini, Flarris et al.
1998; Clemmons, Moses et al. 2000; Saukkonen, Amin et al. 2004). The data presented
in this chapter confirm that the acute effects of treatment with rhIGF-I/rhIGFBP-3
complex are sustained over a seven day treatment period, with comparable increases in
concentrations of IGF-I and IGFBP-3 and reductions in growth hormone secretion.
Treatment was well tolerated, with no episodes of severe hypoglycaemia. The original
hypothesis was that suppression of nocturnal growth hormone secretion might lead to
reductions in GFR and urinary albumin excretion rates, however, there was no
discernable change in GFR or albumin excretion rate following administration of rhlGF-
I/rhIGFBP-3 complex. This may reflect differing effects of increases in IGF-I
concentrations and suppression of growth hormone on renal filtration. It has been
reported that administration of rhIGF-I (dose 60mcg/kg tds) leads to increases in
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glomerular filtration rate that are apparent 6 hours following commencement of rhIGF-I
therapy in healthy volunteers (Hirschberg and Kopple 1989; Hirschberg, Rabb et al.
1989; Hirschberg, Brunori et al. 1993; Hoogenberg, Sluiter et al. 1993; Hirschberg and
Adler 1998). Similarly, administration of growth hormone leads to increases in GFR, but
these are not apparent until three days after injection and are thought to be secondary to
rises in IGF-I concentrations rather than a direct effect of growth hormone on the kidney
(Hirschberg, Rabb et al. 1989). Previous studies of short and long-term administration of
rhIGF-I alone to young people with Type 1 Diabetes reported no change in GFR
(Cheetham, Holly et al. 1995; Acerini, Patton et al. 1997).
While there was no discernable effect on GFR, plasma creatinine concentrations were
lower following rhIGF-I/rhIGFBP-3 complex. With no concomitant change in GFR, and
no apparent change in renal tubular function, this may reflect lower protein turnover
following rhIGF-I/rhIGFBP-3 complex treatment, secondary to the known anabolic and
anti-catabolic effects of rhIGF-I (Mauras, Martinez et al. 2000). Detailed studies of
protein turnover using stable isotopes would provide interesting additional insight into
the mechanisms underlying this observation.
In a mouse model of diabetic nephropathy with abnormalities in the growth hormone -
IGF-I axis similar to those seen in humans with Type 1 Diabetes, treatment with a
specific growth hormone antagonist led to reductions in renal expression of IGF-I,
combined with reductions in renal size, glomerular hyperfiltration and albumin excretion
rates (Flyvbjerg, Bennett et al. 1999). However, in these studies circulating
concentrations of IGF-I, in addition to paracrine expression of IGF-I within in the
kidney would have been reduced. In this study, circulating concentrations of IGF-I
increased, but paracrine production may have fallen secondary to suppression of
endogenous growth hormone secretion. Alternatively, the effects of suppressing growth
hormone secretion on chronically increased renal expression of IGF-I and its binding
proteins and subsequent effects on renal haemodynamics may take longer than seven
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days to manifest following commencement of rhIGF-I/rhIGFBP-3 complex therapy or a
higher dose may be needed. ACE inhibitors have effects on GFR within 24 hours in
young people with Type 1 Diabetes (Hollenberg, Price et al. 2003). In addition IGF-I
and growth hormone have effects on GFR that manifest within 6 hours and 3 days
respectively (Hirschberg and Kopple 1989; Flirschberg, Brunori et al. 1993). It is
therefore reasonable to anticipate that any effect on GFR would be manifest after 7 days'
treatment with rhIGF-I/rhIGFBP-3 complex.
There are several differences between this study and the murine study referred to above
and the negative result of this study may reflect differences in the expression of growth
hormone dependent peptides between mouse and man. There are little or no data in
humans pertaining to expression of IGF-I and its receptors within the healthy human
kidney or those of individuals with Type 1 Diabetes. Several studies report a direct
relationship between urinary excretion of IGF-I and AER; but should be interpreted with
caution in the light of a kidney that is leaking albumin, a much larger protein than IGF-I
(Quattrin, Albini et al. 1992; Fujihara, Uemasu et al. 1996; Gill, Toogood et al. 1998).
Nevertheless, human subjects with MA have higher urinary IGF-I than controls without
MA, despite having lower concentrations of free IGF-I (Cummings, Sochett et al. 1998).
However, concentrations of peptide hormones in urine depend not only upon local renal
concentrations but also on tubular function (Hourd, Edge et al. 1991). It is unclear
whether urinary IGF-I excretion mirrors renal paracrine expression of IGF-I, or
represents plasma IGF-I that has been filtered and excreted.
Following treatment with rhIGF-I/rhIGFBP-3 complex, but not placebo, there was an
increase in the urinary excretion of IGFBP-3 but not IGF-I, the significance of which is
not clear from this work. In the absence of increase in the excretion of any other markers
such as RBP or albumin, it appears to be specific for IGFBP-3. In the following chapter,
an apparent induction of IGFBP-3 proteolysis following administration of rhlGF-
I/rhIGFBP-3 complex is reported which may shed some light on this finding. In general,
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following administration of rhIGF-I/rhIGFBP-3 complex, the detectable rise in plasma
IGFBP-3 concentrations is proportionately smaller than that seen in concentrations of
IGF-I. If there is an induction of proteolysis, with subsequent excretion of smaller
fragments of IGFBP-3 in the urine, that may go some way to explaining the discrepancy.
The small sample size of only 6 subjects is a limitation of this work and a larger sample
size may have revealed an effect. However, we may exclude a large effect of rhlGF-
I/rhIGFBP-3 complex on GFR (a change in mean GFR of 30 ml/min/ 1.73m2), which
would have returned our hyperfiltrating subjects to the reference range for GFR.
Following rhIGF-I/rhIGFBP-3 complex treatment; all subjects remained within the
hyperfdtrating range. A larger sample size would detect smaller effects on GFR, but may
not have been clinically relevant.
Finally, other potential confounders cannot be discounted. Treatment with rhlGF-
I/rhIGFBP-3 complex for 7 days led to reductions both in insulin requirements and
plasma insulin concentrations in the 5 hours prior to determination ofGFR. Increasing
insulin concentrations lead to an increase in renal retention of sodium and water and an
increase in GFR (ter Maaten, Voordouw et al. 1999). We therefore might have expected
GFR to decrease secondary to reductions in overnight plasma insulin concentrations
following treatment with rhIGF-I/rhIGFBP-3 complex.
3.5. Conclusions
In conclusion, seven days adjunctive therapy with rhIGF-I/rhIGFBP-3 complex (dose
0.4mg/kg/day equivalent to 80mcg/kg/day IGF-I) was well tolerated and appeared safe.
We observed an increase in overnight insulin sensitivity and a reduction in creatinine
concentration, coupled with a reduction in overnight growth hormone secretion, but did
not observe any changes either in glomerular filtration or urinary albumin excretion
rates. Further work, detailing the effects of longer term adjunctive therapy with rhlGF-
I/rhIGFBP-3 complex in subjects with microalbuminuria on urinary albumin excretion
rates would be of interest, along with larger scale clinical trials of rhIGF-I/rhIGFBP-3 in
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the Type 1 Diabetes population, considering perhaps more clinically relevant outcomes
such as HbAlc, rates of hypoglycaemia and total daily insulin dose along with side
effect profile would be of interest. It would also be of interest to examine the effects of
the growth hormone antagonist, B2036-PEG on GFR and urinary albumin excretion
rates as this should in theory reduce both circulating concentrations of IGF-I in addition
to paracrine IGF-I within the kidney in a fashion analogous to that described in the
mouse model by Flyvbjerg and colleagues.
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Chapter 4: THE EFFECTS OF rhIGF-I/rhIGFBP-3
COMPLEX ON IGFBP-3 PROTEOLYSIS IN Type
1 Diabetes
4.1. Introduction
The laboratory work described in this chapter was performed on samples collected
during a study co-ordinated by Dr Tero Saukkonen which explored the effects of rhlGF-
I/rhIGFBP-3 complex administration (Mecasermin rinfabate, Somatokine, iPLEX™) on
insulin sensitivity in young people with type one diabetes. The study was a dose-ranging
study (0.1 to 0.8mg/kg/day), looking at the effects of increasing doses of rhlGF-
I/rhIGFBP-3 complex on overnight insulin requirements and insulin sensitivity during a
hyperinsulinaemic clamp the following day and demonstrated a dose dependent increase
in overnight insulin sensitivity in addition to increased peripheral insulin sensitivity
during the hyperinsulinaemic clamp (Saukkonen, Amin et al. 2004; Saukkonen, Shojaee-
Moradie et al. 2006). During the analysis of the samples, it was noted that although IGF-
I concentrations rose in a dose-dependent fashion as expected following the
administration of rhIGF-I/rhIGFBP-3 complex, the rise in IGFBP-3 concentrations was
less marked, despite the fact that rhIGF-I/rhlGFBP-3 complex consists of IGF-I and
IGFBP-3 in equimolar proportions. In conjunction with the increases in urinary
excretion of IGFBP-3 demonstrated in the previous chapter, this prompted us to look
more closely at any effects of rhIGF-I/rhIGFBP-3 complex on proteolysis of IGFBP-3.
Western immunoblotting analysis was used in order to investigate any potential effects
of rhIGF-I/rhIGFBP-3 complex on IGFBP-3 proteolysis and modified immunobased
assays were used to quantify urinary concentrations of IGFBP-3. The work described in
this chapter was undertaken in the laboratory ofDr. Ceci Camacho-Hubner, at St
Bartholomew's Medical School, London, UK and I am grateful to her and particularly to
Dr Farideh Miraki-Moud for their guidance and patience.
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4.2. Methods
4.2.1 Study Design
The study was a double blind, randomised crossover study of low (0.1 and 0.2 mg/kg)
and high (0.4 and 0.8mg/kg) dose rhIGF-I/rhIGFBP-3 complex in young people with
type one diabetes versus placebo. All subjects were studied on 3 separate occasions;
receiving placebo on one occasion and rhIGF-I/rhIGFBP-3 complex on the other 2.
Subjects were randomised into 2 groups; group A received placebo, rhIGF-I/rhIGFBP-3
complex 0.1mg/kg and rhIGF-I/rhIGFBP-3 complex 0.4mg/kg in random order and
group B received placebo, rhIGF-I/rhIGFBP-3 complex 0.2mg/kg and rhlGF-
I/rhIGFBP-3 complex 0.8mg/kg on 3 separate occasions in random order. There was a
minimum washout period of 4 weeks between each study.
4.2.2 Subjects
8 young adult subjects with Type 1 Diabetes were recruited for the study (5M, age 13.6-
18.8y, mean HbAlc 9.9% (range 8.0 to 11.9)). All were post pubertal, with Type 1
Diabetes of at least lyears' duration, and were C-peptide negative. All had normal renal,
hepatic and thyroid function and a normal full blood count. None had any evidence of
microalbuminuria or retinopathy. All were treated with a combination of short and long
acting insulins two to four times per day (mean insulin dose 1.0 (0.7 to 1.4)
units/kg/24hr). An additional single subject (subject 9) (male, aged 35y) agreed to
participate in a modification of the study protocol following ethical approval by the
Cambridge Local Regional Ethics Committee.
4.2.3 Study Protocol
Subjects were studied on 3 separate occasions. On each occasion, subjects received 2
subcutaneous injections of either placebo or rhIGF-I/rhIGFBP-3 complex (0.1, 0.2, 0.4
or 0.8mg/kg), 24 hours apart at 1800h. rhIGF-I/rhIGFBP-3 complex was injected by the
subjects under supervision into the anterolateral aspect of the left thigh. All medium and
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long acting insulins were withdrawn 24 hours prior to the first injection and subjects
maintained their blood glucose by using frequent injections of soluble insulin.
Following the second injection, subjects underwent an overnight variable rate insulin
infusion for euglycaemia as described in chapter 2. Plasma samples (Lithium heparin)
taken at baseline (prior to the first injection) and at midnight during the overnight
samples were subsequently analysed for total IGF-I and IGFBP-3 using standard ELISA
techniques and evaluation of IGFBP-3 proteolysis using Western immunoblotting.
A urine sample was collected at midnight on the second night for quantification of
urinary IGFBP-3. Investigation of the forms of IGFBP-3 excreted in the urine was
determined using Western immunoblotting tecniques. Timing of injections and sampling
is shown schematically in Figure 21.
An additional subject (subject 9, male, aged 35y) underwent a modified sampling
protocol as follows. He was admitted to the WTCRF at 1700h on day 1 and an
intravenous cannula was inserted for the purposes of sampling, and a baseline sample
was taken at 1730h. At 1800h he received an injection of rhIGF-I/rhIGFBP-3 complex
(0.4mg/kg). Thereafter, samples were taken hourly until 0600h the following morning.
The following day, he returned to the WTCRF. A baseline sample was again taken at
1730h before he received his second injection at 1800h. Hourly samples were then taken
until 0600h the following morning when he was discharged. He did not undergo
overnight insulin infusion for euglycaemia or a hyperinsulinaemic clamp. Successive
hourly samples were subjected to Western immunoblotting, IGF-I, IGFBP-3 and
quantification of functional IGFBP-3.
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BaselineSample I nje cti on 2 Urineandplasma sample StartofHyperinsulinaei
Injection 1 1800h OOOOh clamp
1800h 0800h
Figure 21: Study Schedule
Diagrammatic representation of the study schedule. Timing of injections and sampling on
each occasion are marked with arrows
4.2.4 Urine Sample Collection, Preparation and Storage
Urine samples were collected at midnight on the second night, during the overnight
period of euglycaemia, 30 hours after the first injection. 20ml samples were collected
into plain falcon tubes and spun at 3000 rpm for 5min to precipitate any debris. 1.5ml
aliquots were then stored at -80°C until analysis.
For Western Immunoblotting and quantification of IGFBP-3, urine samples were
concentrated 10-fold prior to analysis. Samples were defrosted at room temperature and
then concentrated 10-fold at 1500 rpm at 4°C (microfuge filters NMWL 10,000, Sigma,
Dorset, UK). 1600pl of urine was concentrated to 160pl in a microfuge, lOOOOrpm in
400p aliquots. The final volume was determined accurately using a Gilson pipette.
For determination of creatinine, samples were not concentrated prior to analysis.
4.2.5 Laboratory Methods
4.2.5.i Quantitative assay techniques: plasma
Plasma (total) IGF-I concentrations were measured in ethanolic extracts by EUISA,
(DSL, Tooting, London, UK). The sensitivity of this assay was 0.03 ng/mL. Intra-assay
imprecision (CV) was 8.8% and 9.4% at 107 and 262ng/ml respectively.
- Page 90 -
Plasma IGFBP-3 levels were measured by ELISA, (DSL, Tooting, London). The
sensitivity of this assay was 0.04ng/mL. Intra-assay imprecision (CV) was 4.9% and
2.8% at 5.2 and 34.7ng/ml respectively. Equivalent inter-assay imprecision (CV) was
9.7% and 1.9% at 5.2 and 34.7ng/ml respectively.
4.2.5.ii Quantitative Assay Techniques: Urine
All plasma and urine samples were stored at -80°C prior to analysis. For Western
Immunoblotting and quantification of IGFBP-3, urine samples were concentrated 10-
fold prior to analysis. Samples were defrosted at room temperature and then
concentrated 10-fold at lOOg and 4 °C (microfuge filters NMWL 10,000, Sigma, Poole,
Dorset, UK). Urinary concentrations of IGFBP-3 were determined using a commercially
available polycloncal ELISA kit (DSL, Tooting, London, UK). Prior to analysis urine
was concentrated 10 fold (Centricon). The standard method was adapted to incorporate
incubation of samples with the primary antibody for 18 hours at 4°C.
4.2.5.iii Western Immunoblotting
Details of the reagents and methods for Western Immunoblotting are in Appendix 4.
4.2.5. iv Scanning densitometry
Scanning densitometry analysis of the autoradiographs was performed. Firstly, a BioRad
GS-670 scanning densitometer (Global Medical Instrumentation Inc, Ramsey,
Minnesota, USA) was used to scan the autoradiographs and subsequently Molecular
Analyst PDQuest densitometry software was used to quantify bands having subtracted
background (Bio-Rad, Hercules, CA, USA ).
4.2.6 Calculations
Following scanning densitometry of autoradiographs ofwestern immunoblots, the
relative density of each band, including intact IGFBP-3 and any fragments was
expressed as a percentage of the total of the bands in each lane, after having been
corrected for background.
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4.2.7 Statistical Analysis
For the purposes of analysis, data obtained from rhIGF-I/rhIGFBP-3 complex 100 and
200pg/kg and rhIGF-I/rhIGFBP-3 complex 400 and 800 pg/kg were combined as low
dose and high dose respectively in the 48 hour study.
Where data were normally distributed they were analysed using parametric tests.
Urinary concentrations of IGFBP-3 were not normally distributed and therefore were log
transformed (base 10) to permit parametric testing, p values <0.05 (two tailed) were
considered significant throughout.
All analyses were performed using SPSS for Windows, version 10. Student's t-tests for
paired variables were used to compare within individual differences between plasma
IGF-I and IGFBP-3 concentrations at time 0 and time +30h. A multivariate model
incorporating subject ID and rhIGF-I/rhIGFBP-3 complex dose (low dose or high dose)
as fixed factors was used to determine differences in urinary IGFBP-3 concentration
between groups, with Dunnett's post hoc analysis of compared means used to determine
differences between high dose and low dose groups.
Data are presented as mean ± SEM or median (IQR) otherwise stated, p values of less
than 0.05 (2-tailed) were considered to be statistically significant.
4.3. Results
Data are presented as mean ± SEM unless otherwise stated.
4.2.1 Plasma Concentrations ofIGF-I and IGFBP-3
There was no difference in either IGF-I or IGFBP-3 concentrations at time 0 between
placebo, low dose or high dose groups (Table 11). Plasma concentrations of total IGF-I
were higher at time +30h than at time 0 with high dose rhIGF-I/rhIGFBP-3 complex, but
not with placebo or with low dose rhIGF-I/rhIGFBP-3 complex (Table 11). Plasma
concentration of IGFBP-3 did not change between time 0 and time +30h either with low
dose or high dose rhIGF-I/rhIGFBP-3 complex treatment (Table 11). The IGF-I/IGFBP-
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(mg/1) IGF-I/IGFBP-3 molar ratio
Urinary IGFBP-3
(mcg/mmol creatinine)
Time 0 +30h Time 0 +30h Time 0 +3Oh ±3Oh
Placebo 211 ±29 157 ± 26 4.9 ±0.3 4.3 ± 0.2 0.24 ± 0.04 0.20 ±0.03 59 ±9
Low Dose 201 ±44 235 ±53 4.7 ±0.2 4.5 ±0.2 0.23 ±0.05 0.28 ±0.04 127 ±341
High Dose 219 ±33 458 ±70** 5.1 ±0.3 5.0 ±0.2 0.23 ± 0.04 0.48 ±0.07 * 177 ±18 ff
Table 11. IGF-I and IGFBP-3 Concentrations in plasma and urine
Plasma and urinary IGF-I and IGBP-3 concentrations before and after placebo and rhlGF-
I/rhIGFBP-3 complex. * p<0.05 vs pre, ** p<0.005 vs pre, f p<0.05 vs placebo, ft
p<0.001 vs placebo.
4.3.2 IGFBP-3 Proteolysis
Western Immunoblotting of serum samples at time 0 revealed the expected
immunoreactive bands at 45 and 30 kDa (Figure 22). Following rhIGF-l/rhlGFRP-3
complex treatment, at time +30h, 2 additional immunoreactive bands of approximate
sizes 18- and 14- kDa were present which were not there at time 0 in any subject (Figure
22). The fragments were present in 7 out of 8 subjects in the low dose group and in all
subjects in the high dose group.
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Placebo Low Dose High Dose
Figure 22: Western Immunoblot ofSerum iSVw/f/j/esRepresentative Western
Immunoblot of plasma before (time 0) and after (time +30h) placebo, low dose and high
dose rhIGF-I/rhlGFBP-3 complex. Fragments at 14- and 18- kDa following treatment with
rhIGF-I/rhIGFBP-3 complex are shown within the box.Urinary Excretion ofIGFBP-
3
Urinary excretion of IGFBP-3 at time +30h increased in a dose-dependent fashion
following rhIGF-I/rhIGFBP-3 complex treatment; 58.8±9.4 pg/mmol creatinine
following placebo vs 127.0±34.3 following low dose rhIGF-I/rhIGFBP-3 complex and
177.2±17.8 following high dose rhIGF-I/rhIGFBP-3 complex (Table 11, Figure 23).









Dose or rhlGF-l/rhlGFBP-3 Complex
Figure 23: Urinary Excretion ofIGFBP-3
Effects of low dose (0.1 and 0.2mg/kg) and high dose (0.4 and 0.8 mg/kg) rhlGF-
I/rhIGFBP-3 complex on urinary excretion of IGFBP-3 (ELISA). Differences against
placebo explored using a univariate model with urinary BP-3 as the dependent variable,







Figure 24: Western Immunobiot ofUrine Samples
Immunoblot of urine samples +30h following injection of Placebo, low dose and high dose
rhIGF-I/rhIGFBP-3 complex. Fragments of approximate molecular weight 14- and 18-kDa
are present following rhIGF-I/rhIGFBP-3 complex, but not placebo.
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4.3.4 Urinary 1GFBP-3 Fragments
Western Immunoblotting for IGFBP-3 of urine samples taken at time +30h revealed 2
immunoreactive bands of approximate molecular weights 14- and 18-kDa (Figure 24).
Intact IGFBP-3 was not seen.
4.3.5 Timing ofAppearance ofIGFBP-3 Fragments
Subject 9 underwent a modified sampling protocol as described. Briefly, he received 2
injections of rhIGF-I/rhIGFBP-3 complex; 0.4mg/kg 24 hours apart, administered at
1800h as did the other subjects, but he had samples taken hourly overnight following the
first injection, and then again following the second. Blood samples were analysed for
IGF-I concentration and total and functional IGFBP-3 concentrations. Western
Immunoblotting followed by densitometry was then performed on all samples in order to
determine the timing of appearance of the IGFBP-3 fragments.
With only data from one subject, it was not appropriate to perform statistical comparison
between the 2 nights. However, although there was no apparent difference in the
concentrations of total IGFBP-3 between the 2 nights, it appeared that the amount of
functional IGFBP-3 (that able to bind ligand) was increased on the second of the
sampling nights (Figure 25, panels A and B). Similar effects on proteolysis were noted
in subject 9 following rhIGF-I/rhIGFBP-3 complex administration as had been observed
in the previous subjects, with appearance of a fragment of approximately 18 -kDa which
was first detectable approximately 7 hours after the first dose of rhIGF-I/rhIGFBP-3
complex (Figure 25, panels C and D).
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Figure 25: Resultsfrom sequential samples in subject 9
A: Total IGFBP-3 as determined by ELISA. Night 1 solid line and filled squares, night 2
broken line and open squares. B: Functional IGFBP-3. Night 1 solid line and filled
squares, night 2 broken line and open squares. C: Representative immunoblotting showing
the appearance of 18-kDa fragment (within box) 7 hours after the initial injection and its
persistence through to the end of sampling in addition to the immunoreactive bands at 45
and 30 -kDa. D: Densitometry following western immunoblotting from all sequential
samples. Solid line represents 45-kDa IGFBP-3, Broken line 30 -kDa, Dotted line,
fragments.
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4.4. Discussion
The data reported here indicate that, following the administration of rhIGF-I/rhIGFBP-3
complex to young adults with Type 1 Diabetes, there is an induction of the proteolysis of
IGFBP-3, leading to the generation of fragments which are excreted in the urine in a
dose-dependent fashion. The data reported in Chapter 3 suggested that although there is
an increase in the urinary excretion of IGFBP-3 following treatment with rhlGF-
I/rhIGFBP-3 complex, the urinary excretion of IGF-I (the other component of the
complex) remains unchanged, as does the excretion of retinol binding protein, a non¬
specific marker of tubular dysfunction and albumin. This implies that the excretion of
fragmented IGFBP-3 is a specific process, rather than secondary to a general increase in
renal tubular proteinuria following administration of rhIGF-I/rhIGFBP-3 complex.
The administration of IGF-I complexed to its natural carrier protein; IGFBP-3 has been
explored as a way of exploiting the insulin sensitising effects of IGF-I, whilst prolonging
its half-life within the circulation and potentially minimising side effects. To date,
studies of rhIGF-I/rhIGFBP-3 complex administration to adults with both type 1 and
type 2 diabetes, adolescents with Type 1 Diabetes and a small group of subjects with
growth hormone insensitivity syndrome (GHIS) have been reported (Clemmons, Moses
et al. 2000; Clemmons, Moses et al. 2005; Clemmons, Sleevi et al. 2005; Camacho-
Hubner, Rose et al. 2006).
In this chapter, short-term administration of rhIGF-I/rhIGFBP-3 complex to young
adults with Type 1 Diabetes resulted in a dose dependent increase in plasma
concentrations (approximately four fold in the high dose group) whereas the relative
molar increase in IGFBP-3 concentrations was much lower. These increases are similar
to those reported with the administration of rhIGF-I/rhIGFBP-3 complex to adults with
T2D where a 4 to 5 fold increase in total IGF-I concentrations compared with a 1.6 fold
increase in IGFBP-3 concentrations was observed (Clemmons, Moses et al. 2005). In
adults with Type 1 Diabetes a similar, four fold increase in IGF-I was observed,
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although changes in IGFBP-3 were not reported (Clemmons, Moses et al. 2000). In
another study of four subjects with growth hormone insensitivity syndrome (GHIS),
administration of the rhIGF-I/rhIGFBP-3 complex lead to four fold molar increases in
IGF-I concentrations, but only a 1.4 fold increase in IGFBP-3 (Camacho-Hubner, Rose
et al. 2006). Western blotting revealed the appearance of a 30 -kDa band following
administration of the complex, but the authors did not comment on its likely
significance. The data reported here are similar, with IGF-I concentrations increased
four fold, with a much smaller (around 15%) increase in IGFBP-3 concentrations.
Additional data from an additional single subject who underwent hourly sampling from
administration of the first dose of rhIGF-I/rhIGFBP-3 complex indicates that there may
be an increase in 'functional' IGFBP-3, i.e. that which is capable of binding ligand.
Clemmons and co-workers have reported that following administration of rhlGF-
I/rhIGFBP-3 complex to adults with diabetes, there is an induction of IGFBP-3
proteolysis which results in preferential degradation of the non-glycosylated form of the
protein (i.e. the exogenously administered form), with the glycosylated form being
protected (Clemmons, Sleevi et al. 2005). This may lead to an overall increase in
glycosylated IGFBP-3 available for ligand binding, which may in turn result in a more
stable pool of IGF-I within the circulation. However, far more detailed studies involving
larger numbers are required before the exact nature of the effect of administration of
rhIGF-I/IGFBP-3 complex on IGF binding proteins, the ternary complex and IGF-1
bioavailability can be determined.
There are several potential explanations for the apparent lack of increase in plasma
IGFBP-3 concentrations following rhIGF-I/rhIGFBP-3 complex. One possibility is that
the plasma concentrations are increased but that it could not be detected using the
quantification method. However, the assay used, a commercially available ELISA
incorporates a polyclonal antibody that should bind both intact IGFBP-3 in addition to
fragments. Similarly, polyclonal antibodies were used in the Western immunoblot and
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therefore should have detected all forms of IGFBP-3. As the same antibodies were able
to detect increasing amounts of immunoreactive IGFBP-3 in urine, it would appear that
the relatively smaller rise in IGFBP-3 concentrations following rhIGF-I/rhIGFBP-3
complex administration reflects the urinary excretion of fragments rather than the failure
to detect fragments in plasma by the assay.
Alternatively, IGF-I from the complex may be preferentially absorbed over IGFBP-3,
which might not enter the circulation. However, in the preclinical development phase of
rhIGF-I/rhIGFBP-3 complex, it was reported that in rats and monkeys that
administration resulted in binding of the complex to endogenous ALS within the
circulation, indicating that, at least in animals, the complex is intact (Adams, Moore et
al. 1995). The data from subject 9 demonstrate the first appearance of plasma fragments
7 hours after the first injection, indicating that the induction of proteolysis is a relatively
acute phenomenon.
Finally, IGFBP-3 may be degraded following absorption and subsequently cleared from
the circulation. The most plausible explanation for this would be via induction of
intravascular proteolysis with renal clearance of generated fragments. The data presented
in this chapter provide support for this, with demonstration of the appearance of IGFBP-
3 fragments in serum following the administration of rhIGF-I/rhIGFBP-3 complex, with
fragments of similar molecular weight detectable in the urine in a dose-dependent
fashion. The data presented here do not add any additional information regarding the site
of proteolysis, which may have occurred prior to absorption from the injection site,
within the circulation, or within the tissues, for example, the kidney prior to excretion.
Urinary excretion of an N-terminal fragment of IGFBP-3 of approximately 18- -kDa has
been reported to be greater in children than adults and reduced in children with GHD,
increasing following treatment with growth hormone, implying growth hormone
dependency (Spagnoli, Gargosky et al. 1995). In Chapter 3, it was demonstrated that
administration of rhIGF-I/rhIGFBP-3 complex to young people with Type 1 Diabetes
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results in suppression of endogenous growth hormone secretion and therefore a
reduction rather than an increase in urinary IGFBP-3 might be anticiapted. Finally,
increased excretion of an 18 -kDa N terminal fragment of IGFBP-3 in conjunction with
proteolysis has been described in adolescents with Type 1 Diabetes and
microalbuminuria when compared to controls without microalbuminuria, with urinary
concentration of the IGFBP-3 fragment correlating with proteolysis quantified by
immunoblotting techniques (Spagnoli, Chiarelli et al. 1999). However, in that study, the
urinary IGFBP-3 correlated strongly with albumin excretion rates which might reflect
non specific tubular protein leak rather than a specific process. Alternatively it may be
secondary to the increased growth hormone secretion which is reported in patients with
Type 1 diabetes and microalbuminuria (Amin, Williams et al. 2005).
It is not clear why fragments are excreted, as peptides of this size would normally be
reabsorbed by the renal tubules and recycled. The dose dependent increases in the
urinary excretion of IGFBP-3 fragments following rhIGF-I/rhIGFBP-3 complex may
simply represent a mechanism for excretion of excess, although it would be more likely
that they be reabsorbed, degraded and recycled rather than simply being excreted.
Tubular re-absorption of peptides is an exquisitely ATP dependent process and all
samples were taken following an overnight period of euglycaemia. Small urinary
peptides such as retinol binding protein (RBP) and N-acetyl glucosaminidase (NAG) are
present in up to 60 and 100% respectively of children with diabetes 5 years from
diagnosis, but are not reliable indicators of subsequent microalbuminuria risk, although
they are related to duration of diabetes and HbAlc (Schultz, Dalton et al. 2001). This
implies that the mechanisms for the tubular re-absorption of peptides in young people
with Type 1 Diabetes are somehow impaired and may in part explain these findings.
IGFBP-3 proteolysis has been reported in children with Type 1 Diabetes prior to
commencement of insulin and in diabetic ketoacidosis, i.e. it appears to be a marker for
catabolism (Bereket, Lang et al. 1995). IGF-I has well recognised anabolic effects and it
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is unlikely that our subjects were more catabolic following complex administration.
Indeed, in chapter 3, following administration of rhIGF-I/rhIGFBP-3 complex there was
a reduction in creatinine concentrations in the absence of any change in GFR, implying
an increase in anabolism rather than catabolism (Williams, Yuen et al. 2006).
Clemmons and co-workers reported that following administration of rhIGF-I/rhIGFBP-3
complex to adults with T2D, there is induction of IGFBP-3 proteolysis apparently
specific for the non-glycosylated form (Clemmons, Sleevi et al. 2005). The authors
argued that by acting as a preferential substrate for protease activity, the non-
glycosylated IGFBP-3 protects endogenous glycosylated IGFBP-3 from degradation,
leading to increases in total IGFBP-3 proportionately less than the increases in IGF-I,
but act to increase the half life of IGF-I by increasing stability (Clemmons, Sleevi et al.
2005).
A limitation of this study is the absence of any data from a healthy control population
without diabetes. It is notable that, with the exception of the early human studies in the
development of rhIGF-I/rhIGFBP-3 complex, none of the published work contains a
control group for comparison, with almost all studies being of longitudinal design,
studying individuals prior to and then following administration of rhIGF-I/rhIGFBP-3
complex. These studies, while they lack a control group, do report data from the same
individuals following administration of placebo. In the subjects described here, there
were no detectable fragments of IGFBP-3 in either plasma or urine in any subject either
before or after administration of placebo, which has to be considered as robust control
data and supports the argument that the fragments appear directly as a result of
administration of rhIGF-I/rhIGFBP-3 complex to subjects with type 1 diabetes, although
the precise mechanisms and significance remain unclear.
4.5. Conclusion
Administration of an equimolar rhIGF-I/rhIGFBP-3 complex in people with Type 1
Diabetes leads to disproportionate increases in plasma IGF-1 and IGFBP-3
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concentrations. The demonstration of fragments within plasma and dose-dependent
increase in urinary IGFBP-3 concentrations suggest that this may result from IGFBP-3
proteolysis and subsequent urinary excretion. It is possible that the induction of
proteolysis of IGFBP-3 following administration of the recombinant complex may have
implications for the bioefficacy of the compound.
These data suggest that administration of rhIGF-I/rhIGFBP-3 complex to young adults
with Type 1 Diabetes results in an induction of the proteolysis of IGFBP-3 with
subsequent excretion of fragments of IGFBP-3 in the urine. The significance of these
findings is not clear but an increase in proteolytic activity may lead to an increase in
bioavailable IGF-I and reflect a more subtle mechanism for regulation of availability of
bioactive IGF-I.
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Chapter 5: Conclusions
5.1. Introduction
The central vein of this thesis is the dysregulation of the growth hormone - IGF-I axis
which is present in young adults with Type 1 Diabetes; namely, low circulating
concentrations of IGF-I, with subsequent hypersecretion of growth hormone due to
failure of the negative feedback mechanism. This stems from low concentrations of
insulin within the portal circulation with subsequent reductions in expression of the
hepatic growth hormone receptor and hepatic IGF-I generation. Currently, despite the
development of novel insulin analogues and technology such as CSI1 and glucose
sensors, the alternatives for insulin replacement in adolescents with Type 1 Diabetes
remain far from physiological. The eventual development of closed loop systems, may
achieve normoglycaemia for the majority of the time, but optimisation both of glucose
sensing technology and algorithms has yet to be achieved (Hovorka 2006). Despite this,
insulin administration will remain peripheral and, as such the dysregulation of the
growth hormone - IGF-I axis will only be partially corrected (Amiel, Sherwin et al.
1984). Insulin delivery to the portal vein as part of a closed loop system is unlikely to be
a viable alternative, although peritoneal delivery is being actively explored as an
alternative (Gin, Renard et al. 2003).
5.2. The Strengths and Weaknesses of the Reported Studies
The work detailed in this thesis demonstrates the limitations of physiological studies in
the human (or indeed in any other whole animal system); in that it is impossible to
manipulate one component of a complex and finely regulated system without affecting
others. Antagonism of the actions of growth hormone leads to reductions in circulating
IGF-I concentrations and increasing IGF-I concentrations leads to suppression of growth
hormone secretion and the more subtle effects, particularly at the cellular level can only
be surmised. The beneficial effects of specific growth hormone blockade overnight,
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apparently mediated by an effect on lipolysis, were not observed during the
hyperinsulinaemic clamp which may be due to the inevitable consequence of growth
hormone antagonism, reductions in IGF-I concentrations. Conversely, when IGF-I was
replaced in the form of rhIGF-I/rhIGFBP-3 complex, as well as increases in IGF-I, we
observed the anticipated reductions in endogenous growth hormone secretion. Growth
hormone and IGF-I both lead to increases in glomerular filtration rate, so it might be that
the effects of growth hormone suppression on GFR were counteracted by the opposing
effects of IGF-I. In addition we had no information regarding paracrine effects ofgrowth
hormone on intrarenal IGF-I expression; to gather such information would require serial
renal biopsies, and, while it would undoubtedly be of scientific interest, would be
inappropriately invasive.
Some insight into the potential knock on effects on manipulation of the growth hormone
- IGF-I axis was obtained from the work on IGFBP-3 proteolysis detailed in Chapter 4
although the exact significance of it remains unclear. Administration of IGF-I
complexed with IGFBP-3 led to an apparent induction of IGFBP-3 proteolysis, which
presumably reflects an effect on the subtle regulation of IGF-I bioavailability although
the significances of this remain unclear. The excretion of fragments of IGFBP-3 in the
absence of any evidence of a non specific increase in tubular protein loss, and in the
absence of an increase in urinary IGF-I concentrations is extremely interesting as in
theory the fragments should be reabsorbed and their amino acids recycled. We were not
able to determine whether the excreted fragments were filtered and not reabsorbed or
whether they were actively excreted by the renal tubules. The significance of these
observations is hard to interpret in the context of these studies but may have implications
for the bio-efficacy of rhIGF-I/rhIGFBP-3 complex.
The use of animal models and cell biology allow more detailed and invasive study of
biological parameters, however the findings have to be interpreted with caution when
considering the human. In particular, while a great deal of detail can be gleaned from
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animal models such as knock out mice, the effects of a gene knockout from birth in a
different species will be different to the situation of a human who develops autoimmune
mediated diabetes in childhood and who has previously had normal physiological
regulation of growth hormone and its dependent peptides. Cell biological techniques,
while giving some insight into the intracellular pathways, have yet to reveal the full
extent of the subtle and dynamic interplay between the different signalling pathways.
The information from all sources should be taken and interpreted appropriately.
Ultimately, however, if avenues such as manipulation of the growth hormone IGF-I axis
in Type 1 Diabetes are to be explored, either as a tool to further our understanding of
physiology, or as a potential therapeutic intervention, the biological effects, along with
safety profiling have to be understood in the applicable situation, namely the human.
5.3. Limitations of the Methodology
The methods used in this work to explore human physiology can broadly be divided into
2: those attempting to model normative physiology as far as possible; for example the
overnight studies which detail the overnight requirements for euglycaemia and the
hyperinsulinaemic clamp methodology which uses an extreme in order to maximally
stimulate glucose utilisation. It could be argued that the former are both more clinically
and physiologically relevant in the adolescent with Type 1 Diabetes. Particularly in the
work on selective growth hormone blockade, where the effects appeared to be mediated
via growth hormone's effects on lipolysis, the overnight studies revealed more than the
hyperinsulinaemic clamp where even the low dose of insulin used in the first step was
sufficient to completely suppress lipolysis, thereby ameliorating any discemable effects
on hepatic insulin sensitivity. Although the hyperinsulinaemic clamp is without doubt
the gold standard method for assessing insulin sensitivity, it should be remembered that
it was developed for the investigation of individuals with insulin resistance and type 2
diabetes and as such may not be the most useful tool for use in young adults with typel
diabetes, particularly when exploring effects which are likely to be related to effects on
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systems such as lipolysis which are exquisitely sensitive to insulin. Alternative methods
such as utilising cold isotope modelling techniques during steady state euglycaemia
during the overnight period may be a more useful tool.
5.4. Adjunctive therapy in Type 1 Diabetes
The work presented in this thesis represents detailed physiological studies in small
numbers of adolescents and young adults with Type 1 Diabetes. To date there have been
no further studies of specific growth hormone blockade in either type 1 or type 2
diabetes published in the scientific literature. Two further avenues would be of interest
in the young adult diabetic population with this approach. Firstly, the study of renal
physiology and urinaiy albumin excretion rates following administration of a growth
hormone antagonist to humans would be of interest, especially in the light of the
extremely encouraging animal data. Secondly, given the reductions in overnight insulin
requirements following specific growth hormone blockade, larger scale clinical trials to
look in detail at clinical efficacy as well as to investigate long term safety data would be
of interest as if increasing insulin requirements towards the dawn were ameliorated by a
growth hormone antagonist. As such, achieving fasting blood glucose concentrations
within target without concurrent nocturnal hypoglycaemia may be more achievable,
however, the concomitant effects of further reductions in IGF-I would have to be
considered. It would be interesting to compare both doses (5 and lOmg) as we observed
reductions in overnight insulin requirements with the 5mg dose without significant
reductions in IGF-I.
With respect to IGF-I, given either as rhIGF-I alone, or complexed to IGFBP-3, there is
now a reasonably extensive literature pertaining to its use in both type 1 and type 2
diabetes, incorporating both physiological studies and longer term clinical trials. In
general, adjunctive therapy with rhIGF-I led to reductions in insulin requirements and in
1 long term clinical trial in adolescents with Type 1 Diabetes, there were reductions in
HbAlc over 3 months which were unfortunately not sustained over 6 months. This may
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have been related to concordance issues and it must be acknowledged that enthusiasm
for any additional therapy to insulin in young adults with Type 1 Diabetes which
requires another injection on a day to day basis is likely to wane with time. The potential
development of rhIGF-I was abruptly terminated in the late 1990s due to concerns
regarding a high incidence of worrying side effects observed in patients using high
doses. rhIGF-I/rhIGFBP-3 complex was developed as an alternative in the hope that the
complex would be more stable and confer a more pharmacokinetically favourable profile
with fewer dose related side effects. It has yet to be adequately established whether this
is the case and rhIGF-I/rhIGFBP-3 complex is no longer being pursued as a therapy in
the spectrum of insulin resistance.
5.5. Final Conclusions
The work towards this thesis has furthered understanding of the physiology of the
growth hormone - IGF-I axis in adolescents with diabetes. Ultimately in the human
model things can not be described in exquisite detail but nonetheless the importance of
such studies should not be underestimated. Manipulation of parameters of the growth
hormone - IGF-1 axis in an attempt to restore more normative physiology, either by the
suppression of growth hormone secretion or by the pharmacological blockade of its
actions have been described. The studies incorporate detailed physiological
methodology to quantify parameters of insulin sensitivity, carbohydrate and fat
metabolism and renal physiology and are therefore expensive and time consuming to
perform in only small numbers of subjects. Such studies provide valuable insight into
the roles of different components of growth hormone and its dependent peptides in the in
vivo human model and it is vitally important to explore in detail the physiological effects
of such interventions in detail prior to any larger scale trials of clinical efficacy in order
to fully detail their effects.
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Appendices
Appendix 1: Titration of Insulin Dose During Growth Hormone Antagonist Study
Active dose titration should always seek to achieve the best glycaemic control.
A 1.1 Run In Phase
Insulin dose should be titrated according to blood glucose values from home blood
glucose monitoring.
A 1.1.1 Long Acting:
Intermediate acting (NPH / insulatard) should be titrated according to fasting / pre
breakfast blood glucose (target range 5 to 8 mmol/1) in those on multiple injection
therapy (MIT) and additionally to pre-dinner values in in those on tds regimens (target
range 5-8 mmol/1).
The NPH dose should be lowered if blood glucose values fall below the target range for
3 consecutive days or if there are episodes of symptomatic hypoglycaemia. Decrease the
dose ofNPH by at least 10% but not more than 20%.
The NPH dose should be increased if blood glucose levels are higher than target range
for at least three consecutive days. Increase the dose ofNPH by at least 10% but not
more than 20%.
A1.1.2 ShortActing:
Soluble insulin should be injected 20 to 30 minutes before a meal and rapid acting
insulin analogues should be injected 5 minutes before meals.
The titration of short/rapid acting insulin should be according to pre-lunch, pre-dinner
and pre-bed blood glucose values (pre-dinner and pre-bed in tds regimens). The pre-
lunch / dinner value should be between 5-8 mmol/L and the pre-bed value should be
between 8-12mmol/l. If blood glucose is higher than target for more than 3 days, then
increase short acting insulin by 10% of the dose. If blood glucose is lower than target for
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3 consecutive days or in the event of symptomatic episodes of hypoglycaemia, short
acting insulin should be decreased by 10% of dose.
A 1.2 During Treatment
Those subjects taking rhIGF-I/IGFP-3 are likely to need to reduce their insulin dose by
25 to 30%. All subjects should reduce their insulin by 20% (both long and short acting
components) following their second injection.
Thereafter, titrate insulin dose according to blood glucose values.
A 1.2.1 Long Acting:
Intermediate acting (NPH / insulatard) should be titrated according to fasting / pre
breakfast blood glucose (target range 5 to 8 mmol/1) in those on multiple injection
therapy (MIT) and additionally to pre-dinner values in in those on tds regimens (target
range 5-8 mmol/1).
The NPH dose should be lowered if blood glucose values are below the target range for
one day or if there are episodes of symptomatic hypoglycaemia. Decrease the dose of
NPH by at least 10% but not more than 20%.
The NPH dose should be increased if blood glucose levels are higher than target range
for at least two consecutive days. Increase the dose ofNPH by at least 10% but not more
than 20%.
A 1.2.2 Short Acting:
Soluble insulin should be injected 20 to 30 minutes before a meal and rapid acting
insulin analogues should be injected 5 minutes before meals.
The titration of short/rapid acting insulin should be according to pre-lunch, pre-dinner
and pre-bed blood glucose values (pre-dinner and pre-bed in tds regimens). The pre-
lunch / dinner value should be between 5-8 mmol/L and the pre-bed value should be
between 8-12mmol/l. If blood glucose is lower than target for 1 day, or in the event of
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symptomatic episodes of hypoglycaemia, short acting insulin should be decreased by
10% of dose. If blood glucose is higher than target for more than 3 days, then increase
short acting insulin by 10% of the dose.
A1.3 Soluble Insulin Dose Prior to Overnight Euglycaemic Clamp
Long acting insulin was omitted for the 36 hrs prior to admission for the overnight
insulin infusion for euglycaemia. During this period, subjects liaised closely with a
member of the team who was not directly involved in the overnight insulin infusion (Dr
Kevin Yuen). Soluble insulin (actrapid) was used in place of evening long acting by
giving approximately 30% of the usual dose of isophane, or 50% of the usual dose of
glargine. Thereafter, actrapid was given with meals according to blood glucose. If the
blood glucose was above 10mmol/l pre meal, the subject's usual dose was increased by
10 to 15%. There were no problems with hypoglycaemia or ketotic hyperglycaemia in
any subject during the 36hrs prior to admission following withdrawal of basal insulin.
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Appendix 2: Reference Chart for overnight sampling
Clock Sample Vol Blood Growth Free D2 D5
Time No. ml glucose Hormone Insulin NEFA ACA B-OHB BP-1 Glucose Glycerol
17:30 Base 1 3 X X X
17:45 Base 2 2 X X
18:00 1 8 X X X X X X X
18:15 2 2 X X
18:30 3 3 X X X
18:45 4 2 X X
19:00 5 8 X X X X X X X
19:15 6 2 X X
19:30 7 3 X X X
19:45 8 2 X X
20:00 9 8 X X X X X X X
20:15 10 2 X X
20:30 11 3 X X X
20:45 12 2 X X
21:00 13 8 X X X X X X X
21:15 14 2 X X
21:30 15 3 X X X
21:45 16 2 X X
22:00 17 8 X X X X X X X
22:15 18 2 X X
22:30 19 3 X X X
22:45 20 2 X X
23:00 21 8 X X X X X X X
23:15 22 2 X X
23:30 23 3 X X X
23:45 24 2 X X
00:00 25 8 X X X X X X X
00:15 26 2 X X
00:30 27 3 X X X
00:45 28 2 X X
01:00 29 8 X X X X X X X
01:15 30 2 X X
01:30 31 3 X X X
01:45 32 2 X X
02:00 33 8 X X X X X X X
02:15 34 2 X X
02:30 35 3 X X X
02:45 36 2 X X
03:00 37 8 X X X X X X X
03:15 38 2 X X
03:30 39 3 X X X
03:45 40 2 X X
04:00 41 10 X X X X X X X X X
04:15 42 5 X X
04:30 43 5 X X X
04:45 44 5 X X
05:00* 45 10 X X X X X X X X X
05:15 46 2 X X
05:30 47 5 X X X
05:45 48 2 X X
06:00 49 10 X X X X X X X X X
06:15 50 2 X X
06:30 51 5 X X X
06:45 52 2 X X
07:00 53 10 X X X X X X X X X
07:15 54 2 X X
07:30 55 5 X X X X X
07:35 56 3 X X X
07:40 57 3 X X X
07:45 58 3 X X X X
07:50 59 3 X X X
07:55 60 3 X X X
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Clock Sample Vol Blood Growth Free D2 D5
Time No. ml glucose Hormone Insulin NEFA ACA B-OHB BP-1 Glucose Glycerol
08:00 61 10 X X X X X X X X X
08:05 0.5 X
08:10 0.5 X
08:15 62 2 X X
08:20 0.5 X
08:25 0.5 X
08:30 63 5 X X X X X
08:35 0.5 X
08:40 0.5 X
08:45 64 2 X X
08:50 0.5 X
08:55 0.5 X
09:00 65 10 X X X X X X X X X
09:05 0.5 X
09:10 0.5 X
09:15 66 2 X X
09:20 0.5 X
09:25 0.5 X
09:30 67 5 X X X X X
09:35 68 3 X X X
09:40 69 3 X X X
09:45 70 3 X X X X
09:50 71 3 X X X
09:55 72 3 X X X
10:00 73 10 X X X X X X X X X
10:05 0.5 X
10:10 0.5 X
10:15 74 2 X X
10:20 0.5 X
10:25 0.5 X
10:30 75 5 X X X X X
10:35 0.5 X
10:40 0.5 X
10:45 76 2 X X
10:50 0.5 X
10:55 0.5 X
11:00 77 10 X X X X X X X X X
11:05 0.5 X
11:10 0.5 X
11:15 78 2 X X
11:20 0.5 X
11:25 0.5 X
11:30 79 5 X X X X X
11:35 80 3 X X X
11:40 81 3 X X X
11:45 82 3 X X X X
11:50 83 3 X X X
11:55 84 3 X X X
12:00 85 10 X X X X X X X X X
12:05 2 X X
12:10 2 X X
12:15 86 3 X X X X X
12:20 2 X X
12:25 2 X X
12:30 87 5 X X X X X
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Appendix 3: Computer Program for Hyperinsulinaemic Euglycaemic Clamp
During the hyperinsulinaemic clamp, blood glucose was controlled using a computer
programme on laptop computer (PC). The programme is designed to maintain
euglycaemia at a level set by the investigator (in this case, all subjects were rendered
euglycaemic at 5mmol/l) (Matthews, Edge et al. 1990).
Age, sex, weight and initial blood glucose of the subject is entered into the programme
which subsequently calculates dextrose infusion rates based on the blood glucose target.
Thereafter, blood glucose concentrations are entered every 5 minutes and the
programme accumulates an individual-specific array of blood glucose response to
changes in dextrose infusion rate in order to titrated individuals to the euglycaemic
target.
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Appendix 4: Western Immunoblotting Methods
A4.1 Gel Preparation: Solutions
A4.1.1 30% Acrylamide Stock Solution
100g acrylamide (Sigma A-9099)
2.7g N-N'-methylene-bis-acrylamide (Sigma M-7256)
Add 250ml deionised water to the acrylamide bottle and mix until fully dissolved
(approximately 30min).
Add the bis-acrylamide and bring to the final volume with water.
Add approximately lOOmg Amberlite MB-1 (Sigma MB1-A), mix briefly and filter
through 0.22pm filter using a vacuum filtration unit.
De-gas the solution and store at 4°C in the dark.
A4.1.2 Resolving Buffer (1.5M Tris-basepH 8.8)
90.85g Tris-base
Add 400ml deionised water
pH to 8.8 with concentrated HC1 when the solution is cold
Make up to final volume of 500ml and store at 4°C.
A4.1.3 Stacking Buffer (0.5M Tris-basepH 6.8)
30.3g Tris-base (Sigma T1503)
Add 400ml deionised water
pH to 6.8 with concentrated HC1 when the solution is cold
Make up to final volume of 500ml and store at 4°C.
A4.1.4 Ammonium persulphate (APS, Gibco BRL Cat.No.5523UA)
10% weight/volume solution to be prepared fresh as needed
250mg APS
2.5ml deionised water
A4.1.5 SDS (Lauryl sulphate) (Sigma L-3771)
lOg SDS (caution, wear a face mask when weighing)
Mix with 100ml deionised water and filter through Whatman 1 qualitative paper
Store at room temperature (may require warming in a water bath to dissolve fully prior to
use)
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A4.1.6 Gel Apparatus (Hoefer Minigel1)
Clean all glass and aluminium plates thoroughly with 70% EtOH.
Grease the gasket slightly with petroleum jelly (do not use too much)
Arrange the sets into the gel holder; order as follows; aluminium plate, spacers, glass
plate). Insert as many fillers at the back as required so that the plates do not fall out when
the clips are in place.
Pouring Gels
A4.1.1 Resolving Gel
Volume Required 4 gels 10 gels
30% Acrylamide 20ml 50ml
Resolving buffer 12ml 30ml
Water 15.1ml 37.8ml
10% SDS 0.48ml 1.2ml
10% APS 0.36ml 0.9ml
TEMED2 24pi 60pl
Treat sufficient acrylamide to make both the resolving and stacking gels with amberlite for
lOmin and filter through Whatman l qualitative paper. Mix the acrylamide, resolving
buffer and water together and de-gas under vacuum for 10 minutes.
Add the 10% SDS and shake gently (care, this will froth if you are too vigorous), followed
by the 10% APS and finally the TEMED.
Once the TEMED has been added, polymerisation will start.
Pour the gel into the apparatus to approximately 0.75cm below the base of the spacer
comb. Tap the apparatus firmly to ensure the even distribution of the gel and top up as
required.
Mix n-butanol solution (50% water, 50% butanol ) and add 300pl to the top of each gel.
Cover the apparatus with parafilm and leave for at least 2 hours at room temperature to
polymerise.
1 Hoefer Mighty Small II vertical slab unit 8 by 7cm gel
2 N,N,N1,N1-tetramethylethylenediamine SIGMA T9281
3 SIGMA BT 105
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A4.1.2 Stacking Gel
Volume Required 4 gels 10 gels
30% Acrylamide 1.6ml 4ml
Stacking buffer 3ml 7.5ml
Water 7.2ml 18.1ml
10% SDS 0.12ml 0.3ml
10% APS 60pl 150gl
TEMED4 7pl 17.5pl
Mix the prepared acrylamide, stacking buffer, water and 10% SDS (there is no need to de¬
gas this time).
Pour off the n-butanol from the gels and drain onto blotting tissue, then rinse each gel 3
times with water, drain and blot.
Add the APS and TEMED to the stacking gel solution and mix gently.
Pour the stacking gel solution into the gel apparatus, making sure each gel is filled to the
top.
Place the combs into the gels and top up with stacking gel as necessary. Allow to stand at
room temperature for lOmin, then cover the apparatus with parafilm and leave overnight
at 4°C.
Carefully prise the gels apart using a fine spatula and wrap each gel individually in cling¬
film, marking with the date.
Store in a plastic container at 4°C.
Gels will keep for up to 2 weeks.
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
A4.1.1 Electrode Buffer
25mM Tris-base, 192mM glycine5, 0.1% SDS, pH 8.3
Prepare 5x concentrated stock solution:
15. lg Tris-base
4 N,N,N1,N1-tetramethylethylenediamine SIGMA T9281




Add deionised water to 800ml, pH to 8.3, then add water to final volumer 1000ml. Store at
room temperature.
A4.1.2 Loading Buffer (4x concentrated stock solution)
13.3% SDS, 0.42M Tris-base, 0.013% bromophenol blue6, pH 6.5
6.65g SDS
3.3 lg Tris-base
Add water to 50ml and pH to 6.5
Finally add 6.5mg bromophenol blue
A4.1.3 Sample Preparation
Serum Samples: Prepare lx sample buffer, by mixing 3ml water, 0.6ml loading buffer and
0.4ml glycerol7. Mix 5pl serum with 45pl sample buffer and vortex for 5 seconds
Urine Samples: Prepare 4x sample buffer, by mixing 0.6ml loading buffer and 0.4ml
glycerol. Mix 37.5pl 10X concentrated urine with 12.5|al 4x sample buffer and vortex for
5 seconds.
g
Molecular Weight Rainbow Markers : Add 5pl markers to 15pi lx sample buffer and
vortex for 5 seconds (Hossenlopp, Seurin et al. 1986).
Denature all samples at 60°C for 10 minutes.
Loading and running the gel
Grease the gaskets and place in position. Check the gel for bubbles and that the stacking
gel is right to the top, then place it in position and secure it with the clips.
Fill the bottom tray almost to the top with lx electrode buffer and then fill the top chamber
with the same to completely cover the gels.
Remove the comb carefully from the gel and top up as required.
Allow the denatured samples to cool slightly before loading onto the gel (markers; lOpI
per lane, samples 25pi per lane).
Run at 25 to 30mA per gel (200V) for approximately 2 hours or until the dye front nears
the bottom of the gel9.
Membrane Transfer
6 SIGMA molecular biology reagent B5525 = 31,311,51,511- tetrabromophenolsulphonephthalein
7 SIGMA G7893
8 Amersham RPN 756
9
Pharamcia LKB-EPS 500/400 power source.
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A4.1.1 Transfer Buffer (lOx concentrated stock solution)
15mM Tris-base, 120mM glycine, 20% methanol, pH 8.3
18.17g Tris-base
90.08g glycine
Add water to 1000ml.
To make a lx solution, mix 10ml stock solution with 20ml methanol10 and 70ml water.
Adjust to pH 8.3 before using.
A4.1.2 Membrane Preparation
Cut Whatman 3mm chromatography/ filter paper to 6.5 by 8.5cm (8 pieces per gel).
Cut 1 piece of Hybond-C extra transfer membrane11 per gel to 6.5 by 8.5cm (do note
handle directly, wear gloves or use forceps).
A4.1.3 Methods
Turn off the power supply and remove the gel from the apparatus.
Carefully prise off the glass plate from the gel.
Cut off the stacking gel and mark the top right corner of the gel by cutting the corner off
diagonally. Remove the gel from the aluminium plate and place into a tray with lx
transfer buffer.
Wet 4 filter papers in lx transfer buffer and place onto the base of the semi-dry
12
electroblotter .
Wet the transfer membrane in lx transfer buffer and place carefully onto the filter papers.
Place the gel onto the membrane and carefully smooth out any air bubbles.
Finally add a further 4 filter papers wetted in lx transfer buffer.
Run the electroblotter at 27mA per gel (200V) for 90min.
Air dry the membrane onto blotting paper and mark the position of the molecular weight
markers. Store at room temperature.
Western Immunoblotting (Chemiluminescence method)
A4.1.1 PBS-T20 (Phosphate buffered saline, Tween 20)
11,5g Na2HP04.2H20 (Molecular weight 177.99)
2.96g NaH2P04 (Molecular weight 119.98)
5.84g NaCl





Dissolve into 800ml deionised water and adjust the pH to 7.5. Make up volume to 1000ml
with water and finally add 1ml Tween-20.
A4.1.2 10%Milk Solution
Dissolve 5g skimmed milk powder in 50ml PBS-T20
A4.1.3 3% Bovine Serum Albumin
Add 1.5g of BSA 13(ffaction V) to 50ml PBS-T20. Do not mix or stir, but allow to stand at
room temperature until it has dissolved.
A4.1.4 1% Bovine Serum Albumin
Add 0.5g BSA (fraction V) to 50ml PBS-T20. Do not mix or stir, but allow to stand at
room temperature until it has dissolved.
A4.1.5 Immunoblotting the membrane
All washes and antibody incubations should be performed whilst shaking gently.
Take the dried membrane and block in 10% milk solution for 60min at room temperature.
Transfer the membrane into 3%BSA solution and block for a further 30min at room
temperature.
Rinse the membrane briefly with PBS-T20, then wash in PBS-T20 for 15min at room
temperature.
Repeat a further 2 5min washes in PBS-T20.
Prepare the primary antibody (anti IGFBP-314) 1 in 1000 dilution in 1% BSA solution,
5ml per membrane.
Seal membrane and primary antibody solution into a bag and incubate overnight at 4°C.
Remove the membrane from the bag and rinse briefly with PBS-T20.
Wash the membrane once at room temperature for 15min in PBS-T20.
Repeat at least a further 2, 5-min washes in PBS-T20.
Prepare the secondary antibody (1 in 8000 dilution15) in PBS-T20, 5ml per membrane.
Seal membrane and secondary antibody solution into a bag and incubate at room
temperature for 60min.
Remove the membrane from the bag and rinse briefly with PBS-T20.
Wash the membrane once at room temperature for 15min in PBS-T20.
Repeat at least a further 2, 5-min washes in PBS-T20.
13 Albumin Bovine Serum, Fraction V, Sigma A9647
14
Upstate Biotechnology Inc, Lake Placid, NY, USA Cat. # 06-108
15 Anti-rabbit IgG, horseradish peroxidase, Amersham Itl Pic, Bucks, UK. Cat. # NA-934
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Once the washes are completed, keep the membrane in the final wash until you are ready
to perform the chemiluminescent detection.
A4.1.6 Chemiluminescent Detection
This should be performed in the dark room using a commercially available enhanced
chemiluminescent (ECL) detection kit16.
Mix 5ml ECL solution 1 with 5ml ECL solution 2 and pour onto the still wet membrane in
a large weigh boat.
Shake gently by hand for 60 seconds, then remove the membrane and dry briefly on filter
paper, before wrapping the membrane in cling film.
Expose to X ray film for 45 seconds, then develop the film and re-expose if required.
16 Enhanced Chemiluminescent Detection System, Amersham Itl Pic, Bucks, UK Cat. # RPN 2109
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